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The world’s population is ageing rapidly. Currently, people at the age of 60 and over 
represent 12.3% of the global population. By 2050, this number will rise to almost 22%. Our 
knowledge of ageing underlying processes is poor, mostly due to the lack of proper models to 
study it. The straightforward strategy to identify the key genetic players in ageing is the 
detection of genes leading to accelerated ageing observed in patients with so called progeroid 
syndromes (PSs), which are very rare genetic disorders characterised by the fatal and severe 
course of the disease. Clinical features of PSs resemble the physiological processes of ageing, 
with early manifestation of ageing-associated conditions, such as osteoporosis, atherosclerosis 
or cancers. Recently, our group examined a 4½-year-old girl diagnosed with a congenital 
segmental progeria syndrome. Trio-based whole-exome sequencing (WES) led to the 
identification of a de novo variant, located in the Nuclear pre-lamin A Recognition Factor 
(NARF) gene. This mutation, c.1100A>G, changed a highly conserved histidine at position 
367 to arginine (p.His367Arg), and is predicted to be damaging by several in silico prediction 
programs. NARF is an evolutionarily conserved gene that has its homologues in both yeast 
(Saccharomyces cerevisiae, NAR1) and nematodes (Caenorhabditis elegans, OXY-4 or 
Y54H5A.4). In mammals, there is an additional homologue of the NARF gene named iron-
only hydrogenase-like protein 1 (IOP1), also known as nuclear pre-lamin A recognition 
factor-like (NARFL). All four proteins are similar to bacterial iron hydrogenases, but they 
have lost their hydrogenase activity. Functional analysis of the p.His367Arg mutation 
identified in our patient revealed that it interferes with the nuclear localisation of NARF. I 
demonstrated that NARF is able to form homodimers, which are probably important for its 
translocation to the nucleus. I also showed that substitution of the conserved histidine exhibits 
a dominant negative effect on the wild-type NARF, resulting in complete mislocalisation of 
both mutated and wild-type NARF to the cytoplasm. This suggests that dimerisation of NARF 
allows for the generation of unconventional nuclear localisation signal (NLS), and mutation 
prevents proper conformation and nuclear import. In my studies, I was able to determine the 
direct interactions of NARF with two proteins: lamin A and CBX5. Both proteins also interact 
with each other, and have been associated with premature ageing phenotypes. I established 
that the corresponding mutation causes prolonged DNA repair induced by UV-light lesions in 
mouse embryonic stem (mES) cells. In addition, I demonstrated impaired proliferation of 




mouse line generation in my study. KI mES cell injections into blastocysts gave rise only to 
low-grade chimeras without germline transmission. I hypothesise that disturbed nuclear 
transport of the NARF protein and its accumulation in the cytoplasm probably prevent its 
proper functioning within the nuclear compartment of the cell. Detailed knowledge of the 
function of the NARF protein in the nucleus is still lacking. The results described within my 
thesis present another step towards understanding NARF function and the mechanisms 





2.1 Ageing processes  
2.1.1 Physiological ageing processes 
The World Health Organization (WHO) defines ageing as the result of ‘accumulation of a 
wide variety of molecular and cellular damages over time which in turn lead to a gradual 
decrease in physical and mental capacity, a growing risk of disease, and ultimately, death’ 
(World Health Organization, 2017). According to the United Nations, the worldwide number 
of people aged 60 years or over was 962 million in 2017. This is more than twice the number 
of people in this age group in 1980. Moreover, this number is expected to double by 2050, 
when it is predicted to reach nearly 2.1 billion (United Nations, 2017). Life expectancy has 
increased and is still increasing dramatically (Flatt and Partridge, 2018; Salomon et al., 2012). 
This is mostly due to improved environmental conditions, food, water and hygiene, as well as 
improved medical care leading especially to the reduced impact of infectious diseases owing 
to antibiotics and vaccinations (Flatt and Partridge, 2018). With the rapid increase in average 
human life expectancy, there has been a dramatic escalation in age-associated diseases 
(AADs; (Salomon et al., 2012). Due to the limited understanding of physiological ageing and 
the molecular mechanisms underlying AADs, modern medicine offers mostly symptomatic 
treatment. In light of this fact, research on ageing is now the focus of thousands of 
laboratories that specialise in the fields of genetics, molecular and cellular biology, 
biochemistry, and behaviour. Rapid advances in the understanding of mechanisms controlling 
cellular proliferation, differentiation and survival are leading to new insights into the 
regulation of ageing. Ageing process begins in a single cell and then engages particular 
organs, eventually leading to the embrace of the entire body along with its interactions with 
the surrounding environment. Lopez-Otin et al. (2013) categorised the nine commonly 
occurring hallmarks of ageing (Figure 1). Biological ageing includes cellular and molecular 
changes, such as genomic instability, telomere attrition, epigenetic alterations, loss of 
proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, 
stem cell exhaustion, and altered intercellular communication (Lopez-Otin et al., 2013). A 
better understanding of these characteristics separately, as well as interactions between them, 
can help to develop particular interventions and treatments to pave the way for improved 





Figure 1: Key molecular hallmarks of the ageing phenotype. The scheme includes the hallmarks of ageing – 
genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, 
mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication 
(adapted from Lopez-Otin et al., 2013). 
 
2.1.2 Accelerated ageing processes 
Progeroid syndromes (PSs) are very rare congenital disorders characterised by symptoms of 
premature or accelerated ageing. PS patients present features that often mimic normal 
physiological ageing, but they appear at an early age (Carrero et al., 2016; Navarro et al., 
2006; Sinha et al., 2014). Typical ageing characteristics observed in PS patients include 
wrinkled skin, sparse hair, prominent veins, loss of subcutaneous fat, osteoporosis, 
cardiovascular and neurodegenerative disorders, and cancer (Carrero et al., 2016; Lopez-Otin 
et al., 2013; Navarro et al., 2006; Sinha et al., 2014). PSs are mostly monogenic disorders, i.e. 
they are caused by a defect in a single gene. Currently, the Center for Progeroid Syndromes, 
part of the Center for Rare Diseases Göttingen (ZSEG), offers molecular testing for 85 genes 
related to 19 known PSs, e.g. Hutchinson-Gilford progeria syndrome (HGPS), Nestor-
Guillermo progeria syndrome (NGPS), Wiedemann-Rautenstrauch syndrome (WRS), Werner 
syndrome (WS), Cockayne syndrome (CS), xeroderma pigmentosum (XP), and Bloom 




mutations in genes encoding proteins involved in biogenesis and maintenance of the nuclear 
envelope, i.e. LMNA mutations in HGPS or BANF1 mutations in NGPS, or mutations in genes 
encoding proteins responsible for various DNA repair mechanisms present in WS, CS, BS or 
XP (Kubben and Misteli, 2017; Navarro et al., 2006).  
2.2 Lamin A alterations cause premature ageing phenotypes 
In eukaryotic cells, the nuclear envelope surrounds the nucleus and separates the nuclear and 
cytosolic cell compartments (Alberts, 2002). The nuclear envelop is composed of an inner and 
an outer lipid bilayer membrane and nuclear pore complexes, and in metazoan cells, an 
additional nuclear lamina (Gerace et al., 1984; Gerace and Huber, 2012). The nuclear lamina 
is connected to the inner nuclear membrane, and provides its mechanical stiffness and 
stability (Dechat et al., 2010; Dechat et al., 2008; Goldman et al., 2002; Gonzalez et al., 
2011). In addition, it takes part in numerous important cellular processes, such as chromatin 
organisation and remodelling, reorganisation of the nuclear envelope during mitosis, DNA 
replication, DNA damage repair, cell differentiation, cell migration and transcription control 
(Dechat et al., 2008; Goldman et al., 2002; Gonzalez et al., 2011). The nuclear lamina consists 
of V-type intermediate filaments called lamins. According to their sequences, biochemical 
characteristics and expression profiles, lamins have been qualified as A- and B-type. 
Mammalian cells express two major forms of B-lamins, B1 and B2, which are encoded by 
two different genes, LMNB1 and LMNB2. B-type lamins are constitutively expressed, and are 
substantial for embryonic development (Dechat et al., 2010; Dittmer and Misteli, 2011). In 
contrast, A-type lamins (lamins A, C, AΔ10 and C2) are products of the alternative splicing of 
a single gene LMNA, and are expressed in differentiated cells (Dechat et al., 2010; Dittmer 
and Misteli, 2011). All lamins are similar in their domain organisation. They comprise a 
characteristic central α-helical rod domain, N-terminal head and C-terminal tail domains. The 
tail domain contains a nuclear localisation signal (NLS), and in lamins B1, B2 and pre-lamin 
A, an additional CaaX motif in which the ‘C’ is a cysteine, the two ‘a’ represant aliphatic 
amino acids, and the ‘X’ stands for a random amino acid (Figure 2a). The CaaX motif is 
subjected to a course of modifications, including farnesylation of the cysteine and proteolytic 
trimming of aaX by RCE1/ZMPSTE24, followed by carboxymethylation of the farnesylated 
cysteine. Pre-lamin A is subsequently cleaved again by ZMPSTE24 to remove the additional 
15 C-terminal residues (including farnesylated and carboxymethylated cysteine), giving rise 






Figure 2: The structure and post-translational modifications of lamins. (a) All lamins are formed of a short 
N-terminal (head) domain, a central (rod) domain composed of four α-helical domains (1A, 1B, 2A and 2B), and 
a globular C-terminal (tail) domain that contains lamin-specific motifs: a nuclear localisation signal (NLS), a 
fold immunoglobulin motif (Ig-like β-fold), and a CaaX motif (C = cysteine; a = aliphatic amino acid; X = any 
amino acid). (b) Lamin B and pre-lamin A undergo post-translational modifications, including farnesylation of 
the cysteine in the CaaX motif and cleavage by zinc metalloproteinases RCE1 and ZMPSTE24. Farnesylated C 
is subsequently carboxymethylated by ICMT. Pre-lamin A is further subjected to an additional cleavage of 15 
amino acids upstream of the farnesylated/carboxymethylated C, resulting in mature lamin A. FT = farnesyl 
transferase; ICMT = isoprenylcysteine carboxyl methyltransferase; FACE2 = RCE1 (adapted from Burke and 
Stewart, 2013). 
 
Mutations in LMNA cause a spectrum of human diseases, including Hutchinson-Gilford 
progeria syndrome (HGPS or progeria, OMIM#176670), the best known and the best 
characterised progeroid syndrome (De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003). 
The most common mutation in LMNA leading to HGPS is the silent substitution c.1824C>T, 
p.Gly608Gly, which causes activation of a cryptic exonic splice site that induces altered 






This truncated lamin A (also known as ‘progerin') retains the CaaX motif, allowing for 
farnesylation, while lacking the site for internal proteolytic ZMPSTE24 cleavage. Without the 
complete processing of pre-lamin A, the resulting progerin accumulates in cells leading to 
changes in nuclear lamina structure (Figure 3, left panel; (Davies et al., 2009; Eriksson et al., 
2003). Mutations in ZMPSTE24 can also cause accumulation of farnesylated pre-lamin A in 
cells which results in different progeroid disorders such as restrictive dermopathy (RD; Figure 
3, right panel; (Davies et al., 2009). The effects of these mutations underline the importance 
of the nuclear lamina, and show that alterations in nuclear lamina organisation caused by 
impaired lamin A processing and maturation may lead to lamina malfunction which is the 
common cause of severe disorders, such as laminopathies and progeroid syndromes. 
 
 
Figure 3:  Alterations in lamin A processing. Schemes present alterations in pre-lamin A structure caused 
either by the mutations in the LMNA gene (left) or by mutations in the gene encoding ZMPSTE24 
metalloproteinase (right). In patients, both scenarios lead to accumulation of farnesylated pre-lamin A and the 
progeroid phenotype (adapted from Davies et al. 2010). 
 
2.2.1 Molecular pathogenesis underlying HGPS 
Physiological ageing and HGPS share numerous cellular features—such as abnormal nuclear 
shape, genome instability, telomere attrition, and increased DNA damage—and tissue 
pathologies, such as diminished bone density and cardiovascular diseases (Burtner and 
Kennedy, 2010; Vidak and Foisner, 2016). The accumulation of permanently farnesylated 




pathogenesis of HGPS (Vidak and Foisner, 2016). Progerin-expressing cells exhibit the 
altered mechanical properties of the nuclear lamina, culminating in defects in the nuclear 
architecture, such as thickening, stiffness, and blebbing (Dahl et al., 2006; Goldman et al., 
2004). The presence of progerin engenders chromatin disorganisation due to up- and down-
regulations of epigenetic modifiers, chromatin regulatory proteins, and proteins of the 
nucleosome remodelling complexes (Vidak and Foisner, 2016). It has also been shown that 
progerin expression affects genomic stability via its negative effect on DNA damage repair 
mechanisms. This includes the impaired recruitment of DSBs, repair proteins involved in 
homology-directed recombination (HDR), and non-homologues end joining pathways, such as 
RAD51 and 53BP1, or malfunction of the nucleotide excision repair proteins, such as XPA 
(Gonzalo and Kreienkamp, 2015; Liu et al., 2005; Vidak and Foisner, 2016). Telomere 
dysfunction and decreased telomere length are other characteristic features of HGPS cells 
(Decker et al., 2009). It has been identified that mature lamin A and progerin exhibit different 
preferences for interacting proteins (Kubben et al., 2010). Disrupted association between 
progerin and lamin A interacting partner (LAP2α), which ensures proper telomere 
distribution, engenders telomere mislocalisation, disorganisation, and premature senescence in 
HGPS cells (Chojnowski et al., 2015). Interestingly, both the reduction of lamin A and the 
accumulation of farnesylated pre-lamin A result in increased basal and induced levels of 
reactive oxygen species. These observations are driven by alterations in mitochondrial 
function, as elevation and accumulation of ROS eventually engender mitochondrial 
membrane hyperpolarisation and apoptosis. Furthermore, the expression of key ROS-
detoxifying enzymes can also be dysregulated (Sieprath et al., 2015). 
The progressive increase in knowledge regarding the molecular pathways underlying HGPS 
pathogenesis has enabled investigation of potential therapeutic approaches for progeria 
patients. The first successful therapy developed and tested in clinical trials was based on the 
inhibition of pre-lamin A farnesylation via farnesyltransferase inhibitor (FTI) drug lonafarnib, 
which was initially developed as an anti-cancer drug. Lonafarnib administration improved the 
weight gain, the cardiovascular status, and the bone structure of children with HGPS (Gordon 
et al., 2012; Gordon et al., 2014). Nevertheless, it was demonstrated that the presence of FTI 
may activate alternative pathways of protein prenylation through geranylgeranylation; 
therefore, new therapeutic strategies, including combined administration of statins and 
aminobisphosphonates, have been applied and have shown efficient inhibition of both 




Ongoing studies on potential therapies for patients with HGPS are also considering a 
reduction of progerin through upregulation of the autophagy with retinoids and rapamycin, an 
RNA-targeting correction of the splicing defect, and the beneficial effect of resveratrol, which 
increases the deacetylase activity of SIRT1, a lamin A binding protein (Vidak and Foisner, 
2016). 
2.3 Identification of novel diseases-causing genes in the era of NGS 
2.3.1 Next-generation sequencing (NGS) 
In 1977, genome research was revolutionised by the introduction of a new technique for DNA 
sequencing. Sanger and co-workers described a method of sequencing based on the 
termination of the PCR reaction by incorporating dideoxynucleotides into the newly 
synthesised DNA strand (Sanger et al., 1977). It was the beginning of molecular studies that 
allowed sequencing of DNA, known nowadays as first-generation sequencing (Pareek et al., 
2011). Due to the enormous technological development over the years, great progress has 
been made in DNA sequencing methods. Sanger sequencing requires a considerable amount 
of time, especially when analysing large genomic regions, and results in high cost. Therefore, 
there was a concrete need for novel, cost- and time-efficient sequencing methods. The recent 
introduction of second-generation sequencing or next-generation sequencing (NGS) has led to 
significant improvement in DNA sequencing. NGS-based methods are faster and cheaper 
because of much higher throughput by sequencing a large number of DNA strands in parallel 
(Behjati and Tarpey, 2013). Today, NGS has found numerous applications in many fields of 
science, including the analysis of genetic diseases and identification of novel disease-causing 
genes and mutations. The wide availability of different platforms (Garrido-Cardenas et al., 
2017; Liu et al., 2012; Pareek et al., 2011) has contributed to the development of many 
methods for identifying pathogenic mutations, starting from single-gene sequencing, through 
multi-gene panels designed for particular sets of disorders, to the use of whole-exome 
sequencing (WES) to search for new, unidentified genetic variants (Rehm, 2013; Saudi 
Mendeliome, 2015). Despite the fact that NGS is quickly displacing the old sequencing 
methods, Sanger sequencing is still recommended for confirmation of results obtained by the 
new generation methods (Mu et al., 2016). Genome sequencing using the massive parallel 
next-generation sequencing strategies proved to be an effective alternative to locus-specific 
and gene-panel tests for establishing a new genetic basis of rare diseases (Yang et al., 2013). 
Protein coding genes determine only 1% of the human genome; however, include 




the next-generation application to identify new variants within all coding regions of known 
genes. WES coverages more than 95% of the exons, containing disease-causing mutations in 
Mendelian disorders and many disease-predisposing single nucleotide polymorphisms (SNPs; 
Rabbani et al. 2013). In my studies, WES technology has been used to identify disease 
causing variant in NARF gene in a patient diagnosed with PS. 
2.3.2 Validation of novel disease-causing mutations 
NGS has dramatically increased our ability to read information from the human genome, 
including the DNA sequence, transcriptome and epigenome. Application of these data has 
improved the identification of new potentially disease-causing genetic variants. To 
unequivocally recognise new disease-associated genes and to establish the link to disease 
predisposition and/or progression, NGS data require scientific interpretation (Bonjoch et al., 
2019). As a first tool to validate the pathogenicity of variants found (approx. 25.000 in a WES 
analysis), different bioinformatics approaches have been developed and are currently widely 
used. Computational methodologies for predicting the effect of mutations include four main 
categories: sequence conservation, structure analysis, combined (sequence and structure 
information), and meta-prediction (integrated results from multiple predictors; Tang and 
Thomas, 2016). Numerous platforms are available which allow prediction if the identified 
variant may be deleterious, e.g. SIFT (Sorting Intolerant From Tolerant), PANTHER (Protein 
ANalysis THrough Evolutionary Relationships), PolyPhen-2 (Polymorphism Phenotyping 
v2), and their combinations such as CAROL (Combined Annotation scoRing tool; SIFT + 
PolyPhen2; (Bonjoch et al., 2019). Nevertheless, computational bioinformatics analyses alone 
are not sufficient to claim that an identified variant is a disease-causing mutation. Therefore, 
all potential variants need to undergo further scientific validation, including detailed variant 
analysis in different cellular and animal model systems. Flat, two-dimensional (2D) cell 
culture has dominated scientific research for in vitro understanding of the mechanisms of cell 
behaviour in vivo. However, recent studies have shifted towards culture of cells as three-
dimensional (3D) structures that ensures more realistic biochemical and biomechanical 
microenvironments in vitro (Duval et al., 2017). Moreover, recent improvements in 3D cell 
culture techniques allow for creating even more advanced in vitro models that are organoids. 
Both embryonic and adult stem cells can be used to create models of organ development or 
‘in-a-dish’ diseases. Furthermore, organoids based on patient-derived induced pluripotent 
stem (iPS) cells can be used in numerous applications, such as personalised drug analysis or 




(Clevers, 2016). Despite the fact that the rapidly growing field of in vitro research is very 
helpful in human disease modelling, it is not able to fully replace the benefits of testing 
animal models in vivo. Research on ageing frequently uses small invertebrates such as 
Drosophila melanogaster (Piper and Partridge, 2018) and Caenorhabditis elegans (Litke et 
al., 2018); as models with short lifespans, they are very useful in studying ageing. In addition, 
there are numerous mouse lines carrying different genetic mutations that act as ageing or 
ageing-associated disease models (Koks et al., 2016). Interestingly, humans are also 
investigated in ageing research. Centenarians have been used to study epigenetic signatures of 
healthy ageing (Puca et al., 2018). It may even be possible to use life in space as a model for 
ageing, since microgravity causes physiological changes that resemble ageing which are 
restored after re-entry, allowing investigation of ageing both ways – not only during its 
development but also during recovery (Biolo et al., 2003). Combining different in vitro and in 
vivo models with advancing techniques of genome editing has enabled development of 
various tools suitable for validation of newly identified genetic variants in ageing processes, 
progeroid syndromes and other genetic disorders.  
2.4 Genome engineering for gene editing approaches  
High-throughput techniques of DNA sequencing has allowed the identification of many 
potential disease-causing genes, and the number of such genes is still growing rapidly. 
However, the increasing knowledge about disease-causing genetic mutations is not reflected 
in the development of methods for their treatment. Rare genetic disorders are difficult to 
diagnose, and despite the existence of many symptomatic treatments, the majority of them are 
still incurable and often fatal. Currently, gene therapy seems to be the attractive way to treat 
genetic diseases. Gene therapy is based on the concept of replacing defective DNA with 
exogenous, correct DNA (Friedmann and Roblin, 1972; Maeder and Gersbach, 2016). A 
progressive step in gene therapy research was the discovery of the formation of double-strand 
breaks (DSBs) on DNA and the mechanisms for their repair (Takata et al., 1998; Weaver, 
1995). Homology-directed repair (HDR) and non-homologous end joining (NHEJ), which are 
the two major cellular pathways for repair of DNA DSBs, are widely used today in the gene 
editing process (Fernandez et al., 2017; Lee et al., 2016b; Maeder and Gersbach, 2016; Takata 
et al., 1998). Genome editing became faster and easier thanks to the improvement of genetic 
engineering. Genetically engineered nucleases have become an excellent tool for disrupting 
harmful genes and introducing changes at the single base-pair level (Fernandez et al., 2017; 




2.4.1 The history of gene editing methods 
Meganucleases are modified naturally occurring homing nucleases (Maeder and Gersbach, 
2016). Homing nucleases are small proteins (< 40 kDa) which recognise and cleave specific 
DNA sequences to form DSBs and induce homologous recombination. They are able to 
recognise long (14–40 bp) DNA target sites, and are resistant to small changes in these 
targeted sequences; therefore, they are considered to be the most specific naturally occurring 
restriction enzymes (Chevalier and Stoddard, 2001; Jurica and Stoddard, 1999; Kowalski and 
Derbyshire, 2002). The first homing nucleases to be discovered were algal I-CreI from 
Chlamydomonas reinhardtii (Heath et al., 1997; Jurica et al., 1998) and yeast PI-SceI from 
Saccharomyces cerevisiae (Duan et al., 1997). Both nucleases belong to the large 
LAGLIDADG family of proteins containing one or two LAGLIDADG motifs (Belfort and 
Roberts, 1997; Jurica et al., 1998). Currently, genetic engineering is used to manipulate 
homing nucleases and create engineered meganucleases and chimeric meganucleases that can 
recognise and process specifically designed target sites in genomes of different organisms 
(Epinat et al., 2003; Maeder and Gersbach, 2016; Thierry and Dujon, 1992). 
Zinc-finger proteins (ZFPs) form the largest family of transcription factors in eukaryotes 
(Tupler et al., 2001). The first zinc-finger domain was discovered in the Xenopus laevis 
transcription factor IIIA (TFIIIA; (Miller et al., 1985). Because of the ability of zinc-finger 
domains to recognise and bind to specific DNA sequences, ZFPs make another great tool for 
gene editing. Combining zinc-finger domains with the cleavage domain of bacterial 
endonuclease FokI obtained from Flavobacterium okeanokoites (Li et al., 1992) results in the 
formation of artificial chimeric zinc-finger nucleases (ZFNs) that are able to create DSBs near 
to any predesigned DNA sites (Kim et al., 1996; Kim and Chandrasegaran, 1994). However, 
some of the disadvantages of this method are its long synthesis time and the fact that 
appropriate ZFN pairs cannot be designed for each genomic locus (Addgene, 2017).  
Transcription activator-like effectors (TALEs) have been discovered in the plant pathogenic 
bacteria Xanthomonas spp. (Boch and Bonas, 2010; Deng et al., 2012). In nature, TALEs, 
which are delivered to plant host cells by bacteria, bind genomic DNA at certain promoter 
elements leading to activation of expression of genes that are involved in facilitating 
infections. TALEs recognise specific DNA sequences through their central DNA-binding 
domain consisting of tandem repeats. Each repeat is made up of 33–35 amino acids (Boch and 
Bonas, 2010; Deng et al., 2012; Schornack et al., 2008). All tandem repeats have conserved 




[RVDs]). RVD composition determines which nucleotide is recognised by a single repeat 
(Boch et al., 2009; Deng et al., 2012; Moscou and Bogdanove, 2009). Miller and colleagues 
combined synthetic engineered versions of TALEs with the cleavage domain of FokI 
endonucleases (similarly to ZFNs) resulting in new engineered nucleases – transcription 
activator-like effector based nucleases (TALENs; (Miller et al., 2011). An additional 
advantage of this method is the shorter synthesis time of TALENs compared to that of ZFNs 
(Addgene, 2017; Lee et al., 2016b). However, increasing specificity by extending repetitive 
segments also increases the size of the nuclease, making it difficult to introduce TALENs into 
cells (Lee et al., 2016b; Maeder and Gersbach, 2016; Rinaldi et al., 2017). 
2.4.2 CRISPR/Cas technology as a novel gene editing tool 
Today, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-
associated (Cas) system is the most commonly used technique for gene editing. CRISPR were 
discovered in Escherichia coli in 1987 (Ishino et al., 1987), and have been studied extensively 
since then. CRISPR and CRISPR-associated genes (Cas) form an efficient bacterial resistance 
system which protects them against bacteriophage invasion (Barrangou et al., 2007; Garneau 
et al., 2010; Terns and Terns, 2011). Twenty-five years after the discovery of bacterial 
CRISPR/Cas, the first report on the benefits of this system for editing eukaryotic genomes 
appeared. Based on this system, researchers created a simple complex of CRISPR/Cas9 that 
allows recognition of very specific DNA sequences activating DNA cleavage. The DSBs 
produced are then repaired by NHEJ or HDR (Addgene, 2017; Jinek et al., 2012). The native 
CRISPR/Cas systems use two RNAs: CRISPR RNA (crRNA) that guides nucleases to 
specific places in the genome and trans-activating crRNA (tracrRNA) that serves as a scaffold 
for Cas and crRNA and also participates in the maturation of crRNA from its precursor form 
pre-crRNA (Addgene, 2017; Bhaya et al., 2011; Brouns et al., 2008; Deltcheva et al., 2011; 
Wiedenheft et al., 2012). In engineered CRISPR/Cas9 systems, RNAs are simplified and 
condensed into single shorter guide RNA (gRNA; (Addgene, 2017; Fu et al., 2014; Jinek et 
al., 2012). The gRNA is composed of a 20-nucleotide sequence complementary to the 
genomic target and the scaffolding sequence necessary for binding to Cas9. Shorter gRNAs 
have reduced levels of off-target events induced by CRISPR/Cas9 (Addgene, 2017; Fu et al., 
2014). Cas9 proteins are nucleases that specifically cleave DNA, determined by both 
complementarity between gRNAs and targeted DNA sites and the presence of a protospacer-
adjacent motif (PAM) localised downstream of the target sequence (Jinek et al., 2012; 




proteins to bind and cleave double-stranded DNA, and it is distinct for particular nucleases 
(i.e. the most commonly used Cas9 originating from Streptococcus pyogenes recognises the 
5′-NGG-3′ PAM sequence; (Addgene, 2017; Jinek et al., 2012; Mojica et al., 2009). Cas9, 
brought by the gRNA to the appropriate DNA sequence, recognises PAM, attaches to the 
DNA and cleaves 3–4 nucleotides upstream of the PAM sequence, resulting in DNA DSBs 
(Addgene, 2017; Jinek et al., 2012; Sapranauskas et al., 2011). CRISPR/Cas9 can be used to 
modify any desired genomic target as long as the sequence is unique and upstream of the 
PAM sequence. Therefore, a need for more PAM sequences arose, and to solve this problem, 
different variants of modified Cas9 and its homologues are currently used, which, in 
combination with unique gRNAs, give the ability to edit any sequence in the genome 
(Addgene, 2017; Kleinstiver et al., 2015). Compared to ZFNs and TALENs, the 
CRISPR/Cas9 system is easier and faster to synthesise and use, and has become the most 
popular gene-editing tool (Lee et al., 2016b; Maeder and Gersbach, 2016). Less than four 
years after the first report on the use of CRISPR/Cas 9 for gene editing, 2600 CRISPR-related 
publications have appeared in the PubMed database (Addgene, 2017). In my studies, the 
CRISPR/Cas9 system has been applied to generate knock-in (KI) mouse model of progeroid 
syndrome. 
2.5 Nuclear pre-lamin A recognition factor (NARF) 
Initially, NARF was identified as a binding partner of farnesylated pre-lamin A (Barton and 
Worman, 1999). NARF is a 456-amino acid protein, with an expected molecular mass of 
about 52 kDa, encompassing two protein domains characteristic for iron-only hydrogenases: 
iron-hydrogenase large and small subunits (Figure 4). NARF does not display hydrogenase 
activity, and is supposed to develop new functions during evolution (Hackstein, 2005). Barton 
and Worman (1999) demonstrated that NARF is a nuclear protein which interacts exclusively 
with the C-terminal tail of prenylated pre-lamin A. NARF does not bind to mature lamin A or 
prenylated lamin B1. Prenylation (farnesylation) of cysteine in the CaaX motif, but no 
carboxymethylation of pre-lamin A, seems to be required for NARF binding, and enhances 






Figure 4: Predicted structure of nuclear pre-lamin A recognition factor (NARF). The scheme presents 
expected domain organisation in the human NARF protein (prediction with ebi.ac.uk – HMMER tool). The 
prediction tool distinguishes two domains characteristic of iron hydrogenases: large (green rectangle) and small 
(blue ellipse) subunits of iron hydrogenase. They extend from amino acids 92–382 and 393–445, respectively 
(Fe_hyd_lg_C = iron-only hydrogenase large subunit, C-terminal domain; Fe_hyd_SSU = iron hydrogenase 
small subunit). 
 
The NARF gene is quite conserved, and it has its homologues in other eukaryotes, e.g. in yeast 
S. cerevisiae (NAR1) and in the nematode C. elegans (OXY-4 or Y54H5A.4). Both Nar1 and 
oxy-4 proteins have been described as hydrogenase-like proteins (Balk et al., 2004; Fujii et 
al., 2009). In anaerobic prokaryotic cells, hydrogenases are required for the production and 
metabolism of molecular hydrogen (Peters, 1999). In contrast, yeast Nar1 does not function as 
a hydrogenase, but it takes part in biogenesis of cytosolic and nuclear iron–sulphur (Fe/S) 
proteins (Balk et al., 2004). Moreover, Fujii et al. (2009) suggested a potential role for Nar1 
and oxy-4 in the regulation of oxidative stress. nar1 and oxy-4 mutants showed increased 
sensitivity to higher concentrations of oxygen in the environment, which resulted in decreased 
longevity and growth retardation. Interestingly, mutants are sensitive to oxidative damage 
even under normal oxygen culture conditions (Fujii et al., 2009). In mammals, there is an 
additional homologue of NARF, namely iron-only hydrogenase-like protein 1 (IOP1) or 
nuclear pre-lamin A recognition factor-like (NARFL) protein. NARFL has been described as 
an element involved in the biogenesis of cytosolic iron–sulphur proteins (Huang et al., 2007; 
Song and Lee, 2008, 2011; Song et al., 2009). The Narfl knock-out animal model is 
characterised by early embryonic lethality, while gene inactivation in adults resulted in a 
significantly decreased level of cytosolic Fe/S protein leading to premature death (Song and 
Lee, 2011). In addition, NARFL has been described as a protein involved in the regulation of 
hypoxia-inducible factor-1α (HIF-1α) activity. Knockdown of this protein in mammalian cells 
leads to upregulation of HIF-1α under both normal and decreased oxygen conditions, which in 
turn leads to HIF-1α target gene expression (Huang et al., 2007). Taking together, NARFL 
participates in cellular respiration, the production of free radicals and oxidative stress, thereby 
regulating the ageing processes of multicellular organisms (Harman, 2003). 
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3 Aim of the study 
The main aim of this study was the characterisation of a mutation in Nuclear pre-lamin A 
Recognition Factor (NARF), associated with a novel progeroid syndrome. The mutation in 
NARF was recently identified by our group in a patient diagnosed with a segmental congenital 
progeroid syndrome. Due to the lack of knowledge about the functions of NARF, I began my 
research with basic characterisation of the function of the protein in the cell. I intended to 
establish subcellular localisation of both wild-type and mutated NARF proteins. In addition, I 
wanted to identify partners interacting with NARF and confirm direct interactions, using 
different functional in vitro approaches. I aimed to determine the functional similarity of 
NARF to its homologues by complementation assays performed in a yeast model. Since 
NARF homologues play a role as key regulators of the oxidative stress response, I attempted 
to verify their function in reactive oxygen species (ROS) generation. Genomic instability and 
impaired DNA damage responses are essential hallmarks of ageing; therefore, I aimed to 
examine the impact of mutation on DNA repair mechanisms by induction of DNA lesions in 
cells. Finally, I tried to generate an animal model for the identified mutation. To accomplish 
this, I planned to use the CRISPR/Cas9 system to introduce the mutation corresponding to 
that of the patient into the mouse genome and generate a knock-in mouse line that could serve 
as a new model for progeroid syndromes studies. Taking all thesis aims together, this study 
intended to bring new insights into the pathomechanism underlying the progeroid phenotype 
presented in affected patient, as well as a general insights into the functions of the NARF 
protein.  
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4 Materials and methods 
4.1 Materials 
4.1.1 Chemicals 
Table 1: List of chemicals used during research. 
Chemical Producer 
Agar Carl Roth GmbH, Karlsruhe, Germany 
Agarose 
Peqlab Biotechnologie GmbH, Erlangen, 
Germany 
Ampicillin  Carl Roth GmbH, Karlsruhe, Germany 
Ampuwa (distilled H2O) Frensenius Kabi, Bad Homburg, Germany 
ß-mercaptoethanol 
Gibco™/Thermo Fisher Scientific, Carlsbad, 
USA 
Bacto™ Peptone BD Bioscience, New Jersey, USA 
Bacto™ Yeast Extract BD Bioscience, New Jersey, USA 
CellTiter 96
®
 AQueous One Solution Reagent Promega, Madison, USA 
Chloroform Applichem, Darmstedt, Germany 
Clarity™ Western ECL Substrate Bio-Rad Laboratories Inc., Hercules, USA 
Dimethyl sulfoxide (DMSO) Applichem, Darmstedt, Germany 
DNA ladder (1kb/100bp) Thermo Fisher Scientific, Carlsbad, USA 
DNA Loading Dye (6x) Thermo Fisher Scientific, Carlsbad, USA 
dNTPs Mix (10mM) Thermo Fisher Scientific, Carlsbad, USA 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Gibco™/Thermo Fisher Scientific, Carlsbad, 
USA 
Ethanol 
J.T. Baker/Thermo Fisher Scientific, 
Carlsbad, USA 
Etoposide Sigma-Aldrich/Merck, Darmstedt, Germany 
Formaldehyde Merck, Darmstadt, Germany 
Fetal bovine serum (FBS Superior) Merck, Darmstadt, Germany 
GelRed
®
 Nucleic Acid Gel Stain Biotium, Aachen, Germany 
Halt™ Protease Inhibitor Cocktail (100x) Thermo Fisher Scientific, Carlsbad, USA 
HEPES Sigma-Aldrich/Merck, Darmstedt, Germany 
HisPur™ Cobalt Resin Thermo Fisher Scientific, Carlsbad, USA 
Hydrogen chloride (HCl) 
J.T. Baker/Thermo Fisher Scientific, 
Carlsbad, USA 
Imidazole Carl Roth GmbH, Karlsruhe, Germany 
Isopropanol 




Carl Roth GmbH, Karlsruhe, Germany 
L-Glutamine 
Gibco™/Thermo Fisher Scientific, Carlsbad, 
USA 
Laemmli Sample Buffer (4x) Bio-Rad Laboratories Inc., Hercules, USA 
Leukemia Inhibitor Factor (LIF) Millipore/Merck, Darmstedt, Germany 







Invitrogen™/Thermo Fisher Scientific, 
Carlsbad, USA 
MES monohydrate Sigma-Aldrich/Merck, Darmstedt, Germany 
Methanol 
J.T. Baker/Thermo Fisher Scientific, 
Carlsbad, USA 
Milk powder Carl Roth GmbH, Karlsruhe, Germany 
Mitomycin C  Sigma-Aldrich/Merck, Darmstedt, Germany 
Sodium chloride (NaCl) Sigma-Aldrich/Merck, Darmstedt, Germany 
Sodium hydroxide (NaOH) Merck, Darmstedt, Germany 
Sodium phosphate (Na2HPO4) Sigma-Aldrich/Merck, Darmstedt, Germany 
Non-essential amino acids (NEAA) 




 I Reduced Serum Medium 
Invitrogen™/Thermo Fisher Scientific, 
Carlsbad, USA 
Pansera ES (special designed bovine serum 
for embryonal stem cells) 
PAN-Biotech GmbH, Aidenbach, Germany 
Paraformaldehyde Merck, Darmstadt, Germany 
Penicillin/Streptomycin 
Gibco™/Thermo Fisher Scientific, Carlsbad, 
USA 
Peptone Carl Roth GmbH, Karlsruhe, Germany 
Phosphate buffer Saline (PBS) 
PAN-Biotech GmbH, Aidenbach, Germany 
Gibco™/Thermo Fisher Scientific, Carlsbad, 
USA 
PhosSTOP EASYpack Phosphatase Inhibitor 
Cocktail Tablets  
Hoffmann-La Roche, Basel, Switzerland 
Pierce
®
 RIPA Buffer Thermo Fisher Scientific, Carlsbad, USA 
Precision Plus Protein™ All Blue Standards Bio-Rad Laboratories Inc., Hercules, USA 
ProLong™ Diamond Antifade Mountant 
with DAPI 
Thermo Fisher Scientific, Carlsbad, USA 
Reducing Agent (10x) 
Invitrogen™/Thermo Fisher Scientific, 
Carlsbad, USA 
Restore™ PLUS Western Blot Stripping 
Buffer 
Thermo Fisher Scientific, Carlsbad, USA 
SeeBlue
®
 Plus2 Pre Stained Standard 





Invitrogen™/Thermo Fisher Scientific, 
Carlsbad, USA 
Trihydroxymethylaminomethane (Tris) AppliChem GmbH, Darmstadt, Germany 
Tris/Glycin/SDS running buffer (10x) Bio-Rad Laboratories Inc., Hercules, USA 
Triton-X-100 Carl Roth GmbH, Karlsruhe, Germany 
Tween
®
20 Promega, Mannheim, Germany 
UltraPure™ TBE Buffer (10x) 
Invitrogen™/Thermo Fisher Scientific, 
Carlsbad, USA 
Yeast extract Carl Roth, Karlsruhe, Germany 




Table 2: List of enzymes used during research. 
Enzyme Producer 
0,05% Trypsin-EDTA 
Gibco™/Thermo Fisher Scientific, Carlsbad, 
USA 
Exonuclease I  New England Biolabs, Ipswich, USA 
Platinum
®
 Taq DNA Polymerase 
Invitrogen™/Thermo Fisher Scientific, 
Carlsbad, USA 
Proteinase K Carl Roth, Karlsruhe, Germany 
Restriction enzymes (Fast Digest) 
Invitrogen™/Thermo Fisher Scientific, 
Carlsbad, USA 
Shrimp Alkaline Phosphatase (SAP) Promega, Madison, USA 
T4 DNA Ligase 




Table 3: List of vectors used during research. 
Vector Producer 
pCMV-Myc-N Clontech Laboratories Inc., USA 
hEF1α-GFP 
Kind gift of Dr. Jessica Nolte, Institute of 















 Thermo Fisher Scientific, Carlsbad, USA 
pJET1.2 Thermo Fisher Scientific, Carlsbad, USA 
pET 28a (+) Merck, Darmstadt, Germany 
p415-BFP2 
Kind gift of Prof. Blanche Schwappach, 
Department of Molecular Biology, UMG, 
Göttingen, Germany 
p416 
Kind gift of Prof. Blanche Schwappach, 
Department of Molecular Biology, UMG, 
Göttingen, Germany 
p415-ZZ-tag-TEV 
Kind gift of Prof. Blanche Schwappach, 
Department of Molecular Biology, UMG, 
Göttingen, Germany 
pCSDest C-VC, C-VN, N-VC, N-VN 
Kind gift of Dr. Roland Dosch, Department 




All synthetic oligonucleotides were either purchased from Eurofins Genomics (Ebersberg, 
Germany). 
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Table 4: List of primers used during research. 
Name Sequence 5’→ 3’ Application 
CBX5_EcoRI_F
_Myc 








GAATTCATGGGAAAGAAAACCAAGCGGACA Cloning into 
pET 28a (+) 
vector 
CBX5_XhoI_R_





















































NARF_mut1_R    GGGAATGGGAACTTGCCCTTCTTA 
NARF_mut1_F1    GTTCCCATTCCCCTTTGTGGAGGT 
mutagenesis 
NARF_mut1_R1 CCTCCACAAAGGGGAATGGGAACT 
NARF_mut2_F    TCTTTGTGGAGGTCCTCGCCTGTG 
mutagenesis 
NARF_mut2_R    AGGAATGGGAACTTGCCCTTCTTA 
NARF_mut2_F1    GTTCCCATTCCTCTTTGTGGAGGT 
mutagenesis 
NARF_mut2_R1 CCTCCACAAAGAGGAATGGGAACT 
NARF_mut3_F    GACTTTGTGGAGGTCCTCGCCTGT 
mutagenesis 









NARF_mut6_R    ATGGAATGGGAACTTGCCCTTCTT 
NARF_mut6_F1    AAGTTCCCATTCCATTTTGTGGAG 
mutagenesis 
NARF_mut6_R1   GACCTCCACAAAATGGAATGGGAA 



































GGATCCATGAAGTGTGAGCACTGCACGCGC Cloning into 









































yNar1R_XhoI  CTCGAGTTACCAGGTGCTCCCAACAGAGAC 
yNar1_Fseq GGAGGCGGCCGATTTGTGTT Sequencing 







VNC_hLMNA_ GGGGACAAGTTTGTACAAAAAAGCAGGCTTAAT Gateway 
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α-tubulin WB (1:1000) 
Sigma-Aldrich/Merck, 
Darmstedt,Germany 









Histone H2A.X WB (1:1000) 
Millipore/Merck, Darmstedt, 
Germany 
Penta-His tag WB (1:1000) 










Abcam, Cambridge, UK 
Mouse IgG – isotype 
control 
CoIP (10 µg) Abcam, Cambridge, UK 
Myc Tag, clone 4A6 WB (1:1000) Millipore/Merck, Darmstedt, 
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Life Technologies/Thermo Fisher 






Life Technologies/Thermo Fisher 






Life Technologies/Thermo Fisher 






Life Technologies/Thermo Fisher 
Scientific, Carlsbad, USA 
Goat IgG-Cy3 ICC (1:300) 
Sigma-Aldrich/Merck, 
Darmstedt,Germany 
Goat IgG-HRP WB (1:10000) 
Sigma-Aldrich/Merck, 
Darmstedt,Germany 
Mouse IgG-HRP WB (1:10000) 
Sigma-Aldrich/Merck, 
Darmstedt,Germany 





Table 6: List of kits used during research. 
Kit Producer 
Big Dye Terminator V1.1 and V3.1 Cycle 
Sequencing Kit 
Life Technologies/Thermo Fisher 
Scientific, Carlsbad, USA 
CellROX
®
 Deep Red Flow Cytometry Assay Kit 
Life Technologies/Thermo Fisher 
Scientific, Carlsbad, USA 
CloneJET
™
 PCR Cloning Kit Thermo Fisher Scientific, Carlsbad, USA 
DNase I, Amplification Grade  Thermo Fisher Scientific, Carlsbad, USA 




Life Technologies/Thermo Fisher 
Scientific, Carlsbad, USA 
NE-PER™ Nuclear and Cytoplasmic Extraction 
Kit 
Thermo Fisher Scientific, Carlsbad, USA 
NucleoBond
®
 Xtra Maxi Kit  




 Plasmid  




 BCA Protein Assay Kit  Thermo Fisher Scientific, Carlsbad, USA 
QIAquick Gel Extraction Kit  Qiagen GmbH, Hilden, Germany 
QuantiNova SYBR
®
 Green RT-PCR Kit  Qiagen GmbH, Hilden, Germany 
RTA Transfer Kit (Mini, PVDF) 




 Cloning Kits  Thermo Fisher Scientific, Carlsbad, USA 
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4.1.7 Laboratory materials  
Table 7: List of expendable laboratory equipment used during research. 
Material Producer 
1,5 ml tubes Sarstedt, Nümbrecht, Germany 
2 ml tubes Sarstedt, Nümbrecht, Germany 
384-well PCR plates Thermo Fisher Scientific, Carlsbad, USA 
Centrisart
®
 I (20,000 MWCO CTA) Sartorius AG, Göttingen, Germany 
Cover slips Thermo Fisher Scientific, Carlsbad, USA 
CryoTube Vials Thermo Fisher Scientific, Carlsbad, USA 
Disposable filters Sartorius AG, Göttingen, Germany 
Falcon tubes (15 ml and 50 ml)  Greiner Bio-One, Kremsmünster, Austria 
Glass Pasteur Pipettes Brand GmbH, Wertheim. Germany 
Microscope slides  Thermo Fisher Scientific, Carlsbad, USA 
Mini-PROTEAN
®
 Precast Gels Bio-Rad Laboratories, Inc., Hercules, USA 
Mitsubishi Thermal Paper Standard KP61B Biometra GmbH, Göttingen, Germany 
PCR tubes 
Nippon Genetics Europe GmbH, Düren, 
Germany 
Pipette tips (WB gel loading) 
Biozym Scientific GmbH, Hessisch 
Oldendorf, Germany 
Pipette tips (white long) 
STARLAB International GmbH, Hamburg, 
Germany 
Pipette tips (qRT-PCR) 
STARLAB International GmbH, Hamburg, 
Germany 
Pipette tips (yellow, blue, white short) Sarstedt, Nümbrecht, Germany 
Serological pipettes (5 ml, 10 ml, 25 ml)  




 50 ml syringe 
Henke-Sass Wolf Mikrooptik GmbH, 
Nörten-Hardenberg, Germany 
Surgical disposable scalpels Braun Aesculap AG, Tuttlingen, Germany 
TC flasks (T25 and T75)  Sarstedt, Nümbrecht, Germany 
TC plate (6-cm and 10-cm) Greiner Bio-One, Kremsmünster, Austria 
TC plate (4-well and 24-well) 
Th. Geyer Ingredients GmbH & Co. KG, 
Höxter, Germany 
TC plate (6-well) 
STARLAB International GmbH, Hamburg, 
Germany 
Transfection tubes (13 ml) Sarstedt, Nümbrecht, Germany 
Tubes (13 ml)  Sarstedt, Nümbrecht, Germany 
UV transparent disposable cuvettes  Sarstedt, Nümbrecht, Germany 
 
4.1.8 Instruments 




 Lab Water System Sartorius AG, Göttingen, Germany 
Bio-Link 254 UV crosslinker 
Vilber Lourmat Deutschland GmbH, Baden-
Württemberg, Germany 
Centrifuges Centrifuge 5418 Eppendorf AG, Hamburg, Germany 





Thermo Fisher Scientific, Carlsbad, USA 
Centrifuge Heraeus 
Megafuge 16R 
Thermo Fisher Scientific, Carlsbad, USA 
Centrifuge Heraeus 
Megafuge 1.0R 
Thermo Fisher Scientific, Carlsbad, USA 
Centrifuge Heraeus 
Pico21 
Thermo Fisher Scientific, Carlsbad, USA 
ChemiDoc™ Touch Imaging System Bio-Rad Laboratories, Inc., Hercules, USA 
FAS V Gel Documentation System (CCD-
Sensor) 
Nippon Genetics Europe GmbH, Düren, 
Germany 
Gel Electrophoresis Chambers  Thermo Fisher Scientific, Carlsbad, USA 
Heidolph magnetic stirrer MR 3000 Merck, Darmstedt, Germany 
Heraeus HeraCell 240 incubator Thermo Fisher Scientific, Carlsbad, USA 
Herasafe™ biological safety cabinet  Thermo Fisher Scientific, Carlsbad, USA 











Olympus Corporation, Tokyo, Japan 
ZEISS Primo Vert 
Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany 
Microwave NN-E201WM Panasonic Corporation, Oaza Kadoma, Japan 
Mitsubishi P 95 DE Digitaler Monochrome 
Printer 
Biometra GmbH, Gttingen, Germany 
Mr. Frosty™ Cryo Freezing Container Thermo Fisher Scientific, Carlsbad, USA 
NanoDrop™ OneC Spectrophotometer Thermo Fisher Scientific, Carlsbad, USA 
Neubauer improved chamber 
Glaswarenfabrik Karl Hecht GmbH & Co. 
KG, Sondheim/Rhön, Germany 
New Brunswick™ Innova
®
 40/40R Incubator 
Shaker 
Eppendorf AG, Hamburg, Germany 
pH meter Hanna Instruments™ HI2211-02 
Hanna Instruments Deutschland GmbH, 
Vöhringen, Germany 
PowerPac™ Basic Power Supply Bio-Rad Laboratories, Inc., Hercules, USA 
QuantStudio™ 5 Real-Time PCR System Thermo Fisher Scientific, Carlsbad, USA 
S1000/C1000 Touch  Thermal Cyclers Bio-Rad Laboratories, Inc., Hercules, USA 




Sartorius AG, Göttingen, Germany 
Sartorius LC3200D 
Balance 
Sartorius AG, Göttingen, Germany 
VWR SE 1202 Top 
Load Balance 




Branson Ultrasonic Corp., Lawrenceville, 
USA 
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Thermomixer 5436  Eppendorf, Hamburg, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
Trans-Blot
® 
Turbo™ Transfer System Bio-Rad Laboratories, Inc., Hercules, USA 
Vortex Genie 2™  Bender & Hobein AG, Zurich, Switzerland 
VWR MiniStar Silverline Microcentrifuge VWR International, Radnor, USA 
VWR
® 
Tube Rotator VWR International, Radnor, USA 
 
4.1.9 Buffers and solutions 
4.1.9.1 Agarose gel electrophoresis 
Table 9: Components of agarose gel used for electrophoresis. 
Agarose gel 
Agarose 
0,5 x TBE 
1:20000 GelRed 
 
4.1.9.2 Chemically competent cells 
Table 10: List of buffers and their components used for preparing of competent bacterial cells. 
Buffer Components 
TFB I (1L) 
8,1 g MnCl22H2O 
7,4 g KCl 
1,5 g CaCl2H2O 
3 g KOAc 
150 ml glycerol 
dH20 
pH 6.1 
TFB II (1L) 
11 g CaCl2H20 
0,75 g KCl 
2,1 g MOPS 




Buffers TFB I and TFB II were filtered and autoclaved, respectively, and stored at 4C. 
 
4.1.9.3 Protein extraction 
Table 11: List of buffers and their components used for protein extraction. 
Buffer Components 
Total protein lysis buffer 
10 ml Pierce® RIPA Buffer  
1x Halt™ Protease Inhibitor Cocktail 
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1x tablet of phosphatase inhibitor 
 
4.1.9.4 Western blot 
Table 12: List of buffers and their components used for Western blots. 
Buffer Components 
Transfer buffer  
20% TransBlot Turbo Transfer Buffer (5x) 
20% ethanol 
TBS (10x)  
1,37 M NaCl 
100 mM Tris 
pH 7.6 
TBST 





4.1.9.5 Immunostaining of the cells 
Table 13: List of solutions and their components used for ICC. 
Solution Components 
Fixation solution 4% Paraformaldehyde 
Blocking solution 50mM NH4Cl in PBS 
Permabilization solution 0,2% Triton X-100 in PBS 
 
4.1.9.6 HisPur™ Cobalt Resin purification 
Table 14: List of buffers and their components used for recombinant protein purification. 
Buffer Components 
Equilibration/Wash Buffer 
50mM sodium phosphate 
300mM sodium chloride 
10mM imidazole 
pH 7.4 
Elution Buffer  
50mM sodium phosphate 
300mM sodium chloride 
150mM imidazole 
pH 7.4 
MES Buffer  
20mM 2-(N-morpholine)-ethanesulfonic acid 
0.1M sodium chloride 
pH 5.0 
 
4.1.9.7 Yeast transformation 
Table 15: List of solutions and their components used for yeast transformation. 
Solution Components 
LiAc mix 
1 volume 10xTE pH 7.5 (100 mM Tris-HCl, 
10 mM EDTA) 
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1 volume 1M lithium acetate 
8 volumes autoclaved water 
PEG mix 
8 volumes 50% PEG 
1 volume 10x TE pH 7.5 
1 volume 1M lithium acetate 
 
4.1.10 Media 
4.1.10.1 Media for bacterial culture 













Ampicillin medium   0,1 mg/ml in LB medium 
Kanamycin medium 0,1 mg/ml in LB medium 
LB – agar medium  1,5% agar in LB medium 
Ampicillin plates   1,5% agar in ampicillin medium 
Kanamycin plates  1,5% agar in kanamycin medium 
  
4.1.10.2 Media for cell culture 
Table 17: List of media and their components used for cells culture. 
Medium Components 
FB medium  
DMEM 




20% Pansera ES 
1% penicillin/streptomycin 
0,1 mM NEAA 
0,1 mM ß-mercaptoethanol 




30% culture medium 
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4.1.11 Biological materials 
4.1.11.1 Bacterial strains 
Table 18: List of bacterial strains used during research. 
Strain Producer 
One Shot™ BL21 (DE3) Chemically 
Competent E. coli 
Invitrogen™/Thermo Fisher Scientific, 
Carlsbad, USA 
One Shot™ TOP10F’ Chemically Competent 
E. coli 
Invitrogen™/Thermo Fisher Scientific, 
Carlsbad, USA 
 
4.1.11.2 Cell lines 
Table 19: List of cell lines used during research. 
Cell line Supplier 
EDJ #22 
ATCC® LGC Standards GmbH, Wesel, 
Germany 
HeLa 
ATCC® LGC Standards GmbH, Wesel, 
Germany 
HEK 293T 
ATCC® LGC Standards GmbH, Wesel, 
Germany 
NIH 3T3 
ATCC® LGC Standards GmbH, Wesel, 
Germany 
Human fibroblasts 
Obtained from healthy donors of skin 
biopsies 
 
4.1.12 Sterilization and autoclaving  
Heat-sensitive solutions were filtered using disposable sterile filter units (0.2 to 0.45 μm pore 
size). All solutions which were not heat-sensitive and the plastic equipment were sterilized at 
121°C, 105 Pa for 60 min in an autoclave. Glass wares were sterilized overnight in an oven at 
180°C. 
4.1.13 Online resources 
Table 20: List of online resources and platforms used during research. 
Resource Website 







Exac Browser http://exac.broadinstitute.org 
HMMER https://www.ebi.ac.uk/Tools/hmmer/search/hmmscan 
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Human Gene Mutation Database 
(HGMD) 
http://www.hgmd.org/ 
















Reverse Complement https://www.bioinformatics.org/sms/rev_comp.html 
Sorting Intolerant From Tolerant 
(SIFT) 
https://sift.bii.a-star.edu.sg/ 
The Human Protein Atlas https://www.proteinatlas.org/ 
United Nations (UN) https://www.un.org/en/ 
Varbank https://varbank.ccg.uni-koeln.de 
Webcutter 2.0 http://www.firstmarket.com/cutter/cut2.html 









 FinchTV 1.5.0 Sequences analyzing 
EndNote X9 References processing 
Image Lab™ Software 6.0 WB images analyzing 
Microsoft Excel 2010 Data analyzing 




SnapGene Viewer 4.1.6 Plasmids and sequences analyzing 




4.2.1 Nucleic acids analyses 
4.2.1.1 Polymerase chain reaction (PCR) 
PCR is the technology which is used to amplify known sequence of DNA. It is based on 
changing temperature cycles which provide melting and enzymatic replication of DNA. It 
consists of three major steps: denaturation of DNA double strands, annealing (attachment of 
primers to complementary fragments of DNA) and elongation of new synthesized strand. 
Main components which are required to PCR reaction are: 
- Buffer which provide stable environment for reaction 
- MgCl2 which is required for polymerase activity 
- Mix of all nucleotides (dATP, dTTP, dCTP, dGTP) which are used to extend 
complementary strands (dNTPs) 
- pair of primers which initiate reaction in right place 
- thermostable polymerase (Taq polymerase) which is major enzyme of reaction 
 
Table 22: Standard PCR mixture components. 
Component Volume 
PCR buffer 10x 2,5 µl 
50mM MgCl2 0,75 µl 
10mM dNTPs 0,5 µl 
Forward primer (10 pmol) 0,5 µl 
Reverse primer (10 pmol) 0,5 µl 
Taq polymerase (5 U/µl) 0,15 µl 
DNA 1 µl 
H2O up to 25 µl 
    
Table 23: Standard PCR program. 
Step Temperature Time Number of cycle 
Preliminary denaturation 95C 5 min  
Denaturation 95C 30 s 
35 Annealing 58-62C 30 s 
Elongation 72C 30-60 s 
Final elongation 72C 7 min  
 
Conditions described above depend on melting temperature (Tm) of primers and size of 
product. 
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4.2.1.2 Sequencing PCR  
The most frequently used technique of DNA sequencing is the chain-termination method 
developed by Fredrick Sanger and coworkers in 1977 (Sanger et al., 1977). It provides 
incorporation of dideoxynucleotides (ddNTPs): ddATP, ddTTP, ddCTP, ddGTP into newly 
synthesized complementary DNA strand. Each ddNTP is labeled with fluorescence dye and 
has no 3’-hydroxyl group (3’-OH). 3’-OH group is required for formation of phosphodiester 
bonds and lack of it results in termination of reaction. This leads to the emergence of mixture 
of different-length DNA sequences. The sequence is determined based on length of fragments 
and fluorescent signals. 
Prior to sequencing reaction, genomic fragment of interest was subjected to standard PCR 
reaction described above (see 2.2.1.1 Polymerase chain reaction) using 40 ng od DNA. 
Subsequently, PCR results were checked on agarose gel and subjected for Exo-SAP 
purification process. It is a reaction used for enzymatic cleanup of amplified PCR product. It 
hydrolyzes excess of primers and nucleotides. Purified samples are ready for use in 
downstream applications such as DNA sequencing.  
 
Table 24: Standard Exo-SAP mixture components. 
Component Volume 
SAP 0,3 µl 
EXO I 0,075 µl 
PCR product 8 µl 
H2O up to 10 µl 
 
Table 25: Standard Exo-SAP reaction. 
Temperature Time 
37C 20 min 
85C 15 min 
10C 5 min 
 
To perform sequencing PCR Big Dye Terminator V1.1 and V3.1 Cycle Sequencing Kit was 
used. Reaction was performed using one primer. 
 
Table 26: Standard sequencing mixture components. 
Component Volume 
Buffer (5x) 2,25 µl 
V3.1 0,25 µl 
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Primer 0,25 µl 
Purified PCR product 0,5 µl 
H2O up to 10 µl 
 
Table 27: Standard sequencing program. 
Step Temperature Time Number of cycles 
Preliminary denaturation 96ºC 30 s  
Denaturation 96ºC 10 s 
40 Annealing 55ºC 5 s 
Elongation 60ºC 4 min 
 10ºC 5 min  
 
4.2.1.3 Quantitative Real-Time PCR (qRT-PCR) 
This procedure is applied to quantify the levels of gene expression. The assay is rapid and 
sensitive, and provides detection of amount of PCR product at every cycle of the PCR using 
fluorescence. QuantiNova SYBR® Green PCR Kit was used. The results of qRT-PCR are 
shown as the number of PCR cycles (Ct – cycle threshold) which are necessary to achieve 
particular degree of fluorescence (Ponchel et al., 2003).  
 
Table 28: Standard qRT-PCR mixture components. 
Component Volume 
SYBR-Green 5 µl 
Forward primer 1 µl 
Reverse primer 1 µl 
cDNA (1:10) 2 µl 
H2O up to 10 µl 
 
Reactions were performed in 384-well PCR plates. 
Results were transferred to the Microsoft Excel program. Expression of gene of interest was 
normalized to housekeeping gene and the relative changes in gene expression were estimated 
using 2
-ΔΔCt
 method (Livak and Schmittgen, 2001). 
4.2.1.4 Isolation of DNA fragments from agarose gels using the QIAquick Gel 
Extraction Kit (Qiagen) 
DNA was extracted from the agarose gel using QIAquick Gel Extraction Kit (Qiagen) 
following the manufacturer’s protocols. . Briefly, gel slices were placed in fresh 1,5 ml tubes 
and three gel volumes (gel volume corresponds to the slice weight, 100 mg = 100 μl) of buffer 
QG were added to the agarose gel piece and incubated at 50°C for 10 min.. After gel slice was 
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dissolved 100 µl of isopropanol was added (1 volume) to the sample and vortexed. QIAquick 
spin columns were placed in 2 ml collection tubes. To bind DNA, the solution was applied to 
the columns and centrifuged (all centrifugation steps were performed for 1 min at 13000 rpm). 
Flow-through was discarded and columns were washed with 750 µl of buffer PE. After 5 
minutes of incubation, the column was centrifuged, and flow through was discarded. To 
completely remove residual ethanol, samples were again centrifuged and columns were 
placed in fresh 1,5 ml tubes. DNA was eluted by application of 30-50 µl of buffer EB to the 
center of QIAquick membrane, and a subsequent centrifugation. Extracted DNA was stored at 
-20ºC. 
4.2.1.5 Isolation of genomic DNA from cells 
4.2.1.5.1 DNA extraction using DirectPCR Lysis Reagent 
Cells were collected by trypsinization and washed with DPBS. The cell pellets were 
proceeded immediately or stored at -80ºC. The lysis buffer was prepared by adding 5 µl of 
proteinase K (10 mg/ml) per 100 µl of DirectPCR Lysis Reagent (Tail). The cell pellets were 
resuspended in 105 µl of lysis buffer and incubated overnight at 55C with shaking at 600 
rpm. The next day, samples were incubated at 85C for 45 minutes to inactivate proteinase K. 
To remove the rest of cells the samples were centrifuged for 20 minutes at 14800 rpm (room 
temperature). Supernatant was transferred to fresh tube and stored at 4C. 
4.2.1.5.2 DNA extraction using NaOH/EDTA solution 
Cells were collected by trypsinization and washed with PBS. The cell pellets were proceeded 
immediately or stored at -80ºC. The cell pellets were resuspended in 25 µl of solution 
containing 25 mM NaOH and 0,25 mM EDTA. Samples were incubated for 30 minutes at 
95C. To stop reaction, 25 µl of 40 mM Tris (pH 7.5) was added. DNA samples were stored 
at -20ºC. 
4.2.1.6 Isolation of genomic DNA from tissues using NucleoSpin®Tissue kit 
Genomic DNA extraction procedure was performed according to the manufacture protocol. 
Briefly, small pieces of tissues were placed in 1,5 ml tubes. Lysis buffer was prepared by 
mixing 180 µl of buffer T1 with 25 µl of proteinase K. 200 µl of lysis buffer was added to 
samples and vortexed. Samples were incubated overnight at 56C with 600 rpm shaking. The 
next day, 200 µl of buffer B3 was added and samples were incubated for 10 minutes at 70C. 
Insoluble particles were removed by centrifugation for 5 minutes at 14800 rpm. Supernatant 
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was transferred to fresh 1,5 ml tubes and mixed with 210 µl of 96-100% ethanol. After 
vortexing samples were applied to the NucleoSpin®Tissue columns and they were 
centrifuged for 1 minute at 11000 x g. Collection tubes with flow-through were discarded and 
columns were placed in fresh collection tubes. Columns were washed by adding 500 µl of 
buffer BW and centrifugation for 1 minute at 1000 x g. Flow-through was discarded, columns 
were placed back into collection tubes and washed second time with 600 µl of buffer B5 and 
centrifuged for 1 minute at 11000 x g. To dry membrane, flow-through was discarded and 
samples were centrifuged for 1 minute at 11000 x g. Columns were placed in fresh 1,5 ml 
tubes. To elute DNA 100 µl of buffer BE was applied on the membrane, samples were 
incubated for 1 minute at room temperature and centrifuged for 1 minute at 11000 x g. DNA 
samples were stored at -20C. 
4.2.1.7 Isolation of total RNA from cells 
Cells were collected by trypsinization and washed with PBS. The cell pellets were proceeded 
immediately or stored at -80C. The cell pellets were resuspended in 500 µl of Trizol and 
mixed by pipetting. The samples were incubated for 10 minutes at room temperature and 100 
µl of chloroform were added per each 500 µl of Trizol. Tubes were shaken by hands for 15 
seconds and incubated 5 minutes at room temperature. Samples were centrifuged at 12000 x g 
for 15 minutes at 4C. Aqueous, upper phase was transferred to fresh tube and 250 µl of cold 
isopropanol supplemented with 1 µl of GlycoBlue were added. Samples were vortexed and 
incubated at -20C overnight. The next day samples were centrifuged at 12000 x g for 30 
minutes at 4C. Supernatant was discarded and pellets were washed with 1 ml of 75% ethanol 
and centrifuged at 12000 x g for 5 minutes at 4C. Ethanol was removed and pellets were 
dried at 37C. RNA pellets were resuspended in 50-100 µl of RNase-free water and mixed by 
pipetting. RNA samples were stored at -80C.   
4.2.1.8 cDNA synthesis  
4.2.1.8.1 Removal of genomic DNA using Amplification Grade DNaseI Kit 
1 µg of RNA dissolved in 8 µl nuclease-free water was mixed with 1 µl of 10X Reaction 
Buffer and 1 µl of DNaseI. Mixture was mixed by pipetting and incubated for 15 minutes at 
room temperature. To inactivate the DNaseI 1 µl of Stop Solution was added. Samples were 
incubated for 10 minutes at 70C to denaturate both the DNaseI and RNA and chilled on ice. 
Such prepared samples were proceeded with reverse transcription reaction. 
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4.2.1.8.2 Reverse transcription using RevertAid First Strand cDNA Synthesis Kit 
To prepared RNA samples the following components (in the indicated order) were added: 1 µl 
of Oligo (dT)18 primer, 4 µl of Reaction Buffer, 1 µl of RiboLock RNase Inhibitor, 2 µl of 
dNTP Mix and 1 µl of RevertAid M-MuLV RT. Samples were mixed and centrifuged briefly. 
Reaction was performed for 1 hour at 42C and terminated by 5 minute incubation at 70C. 
cDNA samples were diluted 1:10 in nuclease-free water and stored at -20C.  
4.2.1.9 DNA cloning 
4.2.1.9.1 Amplification of ORFs 
Open reading frames (ORFs) of genes of interest were amplified by PCR using specially 
designed primers. These specific primers allowed flanking amplified ORFs by palindromic 
sequences recognized by particular restriction enzymes. PCR reaction was followed by 
agarose gel electrophoresis and gel extraction of DNA of interest. 
4.2.1.9.2 Blunt-end cloning 
For cloning of blunt-ended PCR products TOPO
®
 Cloning Kits or CloneJET
™
 PCR Cloning 
Kit were used.  
For TOPO
®









 vector and incubated for 30 minutes at 
23C. Reaction was chilled on ice and proceeded with bacterial transformation. 
For JET
™
 cloning 3 µl of purified PCR product were mixed with 5 µl of 2X Reaction Buffer, 
1 µl of pJET1.2 vector and 1 µl of T4 DNA Ligase and incubated for 30 minutes at 23C. 
Reaction was chilled on ice and proceeded with bacterial transformation. 





 plasmid is supplied linearized with single 3´-thymidine (T) overhangs 
for TA cloning and covalently bound topoisomerase I. Taq polymerase has a nontemplate-
dependent terminal transferase activity and adds a single deoxyadenosine (A) to the 3´ ends of 





cloning 4 µl of purified PCR product were mixed with 1 µl 




 vector and incubated for 30 minutes at 23C. 
Reaction was chilled on ice and proceeded with bacterial transformation. 
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4.2.1.9.4 The Gateway® Cloning 
The Gateway
®
 technology was used to generate expression plasmids that were further used in 
Bimolecular Fluorescence Complementation (BiFC) assay. The Gateway
®
 technology is 
based on the bacteriophage lambda site-specific recombination between different attachment 
sites (att) that provides integration of bacteriophage into E. coli chromosome. Gene of interest 
was flanked with specific attB1 and attB2 sequences added to 5’ ends of forward and reverse 
primers, respectively. Flanking was performed by PCR reaction. To generate entry clones, BP 
recombination reaction between attB-flanked DNA fragment and attP-containing donor 
vector (pDONR
™
221) was performed. 3,5 µl of PCR product was mixed with 1 µl of 5x BP 
Clonase™ II and 0,5 µl of pDONR
™
221 vector, and incubated overnight at 25C. To 
terminate BP reaction, 0,5 µl of Proteinase K was added and mixture was incubated 10 
minutes at 37C. Subsequently, bacterial transformation was performed with BP reaction 
mixture. Plasmids were extracted from selected colonies with NucleoSpin
®
 Plasmid (NoLid) 
kit and proceeded with LR recombination reaction. To generate expression clones, LR 
recombination reaction between attL-containing entry clone and attR-containing destinations 
vector (pCSDest C-VC, pCSDest C-VN, pCSDest N-VC, pCSDest N-VN) was performed. 
0,5 µl of pDONR
™
221 entry vector was mixed with 1 µl of 5x LR Clonase™ II, 0,5 µl of 
destination vector and 3 µl of TE buffer, and incubated overnight at 25C. To terminate LR 
reaction, 0,5 µl of Proteinase K was added and mixture was incubated 10 minutes at 37C. 
Then, bacterial transformation was performed with LR reaction mixture. Plasmids were 
extracted from selected colonies with NucleoSpin
®
 Plasmid (NoLid) kit and sequenced. 
Plasmids with no mutations were next transformed into bacteria and multiplied in bigger 
volume of LB medium (150 ml). Final expression plasmids were extracted with NucleoBond
®
 
Xtra Maxi Plus EF kit and used in BiFC assay.       
4.2.1.9.5 Subcloning into expression vectors 
Cloning into expression vectors (pCMV-Myc-N, pCMV-HA-N or hEF1α-GFP) was 
performed by double digestion with particular restriction enzymes on cloning vector 
containing insert of interest as well as on expression vector. This procedure ensures correct 
positioning of insert in the expression vector. Digestion was followed by agarose gel 
electrophoresis and gel extraction. For sticky-end cloning 3 µl of purified insert and 1 µl of 
purified vector were mixed with 2 µl of 5X Reaction Buffer and 1 µl of T4 DNA Ligase and 
incubated for 3 hours at room temperature or overnight at 16C. Reaction was chilled on ice 
and proceeded with bacterial transformation. 
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4.2.1.9.6 Preparation of chemically competent E. coli Top10 F’ cells 
E. coli Top10 F’ bacteria were cultured overnight in 5 ml of LB medium at 37°C and shaking 
at 160 rpm. The next day, 900 μl of cultured bacteria were inoculated in 150 ml of fresh LB 
medium and incubated till OD reach 0,45-0,55. Bacteria were centrifuged at 4°C for 10 
minutes at 2000 rpm. Supernatant was discarded and bacterial pellet was resuspended in 30 
ml of ice-cold TFBI buffer. Bacteria were incubated for 10 minutes on ice and centrifuged 
again at 4°C for 10 minutes at 2000 rpm. Supernatant was discarded and bacterial pellet was 
resuspended in 6 ml ice-cold TFB II. 50 μl aliquots of the bacterial suspension were prepared 
and immediately frozen in liquid nitrogen. Bacterial aliquots were stored at -80°C until use. 
4.2.1.9.7 Transformation of bacteria 
Bacterial aliquot and cloning reaction mixture were incubated for 10 minutes on ice to 
achieve the same temperature. Then cloning mixture was added to the bacteria and mixed 
gently without pipetting. Bacteria were incubated for 30 minutes on ice and then heat shocked 
for 45 seconds at 42C. Bacteria were chilled on ice for 5 minutes and 950 µl of LB medium 
were added. Bacteria were incubated for at least 1 hour at 37C with shaking at 600 rpm. To 
collect bacterial pellets, tubes were centrifuged for 30 seconds at 12000 rpm. Most of 
supernatant was discarded and pellets were resuspended in remain medium (around 50-60 µl). 
Bacteria were inoculated on selective plates and incubated overnight at 37C. 
4.2.1.9.8 Culture of bacteria 
After selection on plates, positive colonies were picked with toothpick and put into LB 
medium supplemented with required antibiotic (50µg/ml). For small-scale plasmid 
purification colonies were incubated in 2,5 ml of medium while for large-scale plasmid 
purification colonies were incubated in 100 ml of LB medium. Bacteria had access to air and 
were incubated overnight at 37C with shaking at 160 rpm. 
4.2.1.9.9 Plasmid DNA purification 
4.2.1.9.9.1 Small-scale plasmid DNA purification using NucleoSpin® Plasmid (NoLid) kit 
Overnight culture was transferred to 1,5 ml tube and centrifuged for 5 minutes at 14800 rpm 
to collect cells. Bacterial pellets were resuspended in 250 µl of Buffer A1 and vortexed. 250 
µl of lysis Buffer A2 were added and samples were mixed by inverting. After 5 minutes 
incubation at room temperature reaction was stopped by adding 300 µl of Buffer A3 and 
inverting till samples turned colorless. To clarify lysate, samples were centrifuged for 10 
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minutes at 11000 x g and supernatant was transferred onto column placed in collection tube. 
To bind DNA, samples were centrifuged for 1 minute at 11000 x g and supernatant was 
discarded. Membranes were washed with 600 µl of Buffer A4 and centrifuged for 1 minute at 
11000 x g. To dry membranes, supernatant was discarded and samples were centrifuged again 
for 2 minutes at 11000 x g. Collections tubes with remained buffer were discarded and 
columns were placed in fresh 1,5 ml tubes. To elute DNA, 50 µl of Buffer AE was added on 
the membrane. Samples were incubated for 1 minute at room temperature and centrifuged for 
1 minute at 11000 x g. Columns were discarded and DNA samples were stored at -20C. 
4.2.1.9.9.2 Large-scale endotoxin-free plasmid DNA purification using NucleoBond® Xtra 
Maxi Plus EF kit 
Overnight culture was transferred to 50 ml falcons and centrifuged for 15 minutes at 4700 
rpm to collect cells. Bacterial pellets were resuspended in 12 ml of Buffer RES-EF. 12 ml of 
Buffer LYS-EF were added and samples were mixed by inverting. For cell lysis, samples 
were incubated for 5 minutes at room temperature. To stop reaction, 12 ml of Buffer BEU-EF 
was added and falcons were inverted till samples turned colorless. Samples were incubated 
for 5 minutes on ice. Meantime, NucleoBond
®
 Xtra Columns with filters were equilibrated 
with 35 ml of Buffer EQU-EF and emptied by gravity flow. Lysates were loaded to the 
equilibrated columns and columns were left to empty by gravity flow. Columns with filters 
were washed with 10 ml of Buffer FIL-EF, emptied with gravity flow and filters were 
discarded. Subsequently, columns were washed with 90 ml of Buffer ENDO-EF and 45 ml of 
Buffer WASH-EF. After each washing columns were emptied by gravity flow. To elute DNA, 
columns were washed with 15 ml of Buffer ELU-EF and the elution fraction was collected in 
50 ml falcon. DNA was precipitated by adding 10,5 ml of isopropanol, vortexing and 
incubation for 2 minutes at room temperature. Precipitated DNA was loaded into 30 ml 
syringe with attached NucleoBond® Finalizer. Sample was loaded in finalizer by slowly 
pressing through the finalizer. Finalizer were washed with 5 ml of 70% ethanol in the same 
way. Finalizers were dried by pressing air through them. To elute DNA, 500 µl of Buffer TE-
EF was slowly pressed through the finalizer and collected in fresh 1,5 ml tube. DNA samples 
were stored at -20C. 
4.2.1.10 Measurement of concentration by NanoDrop™ OneC Spectrophotometer  
NanoDrop™ measurement of concentration is based on spectrophotometry which is the 
quantitative measurement of the reflection or transmission properties of a material as a 
function of wavelength. 
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4.2.1.10.1 Nucleic acids concentration 
Nucleic acids (DNA and RNA) concentrations were measured using measurement pedestal. 
Concentration was based on absorbance at 260 nm and the defined extinction coefficient. 
Blanking was performed using 1,5 µl of water in which the nucleic acids were dissolved. 
Then 1,5 µl of DNA or RNA was put on pedestal and measured. The program estimated the 





c – the nucleic acid concentration in ng/µl 
A – the absorbance in AU        
ε – the wavelength-dependent extinction coefficient in ng-cm/µl 
b – the path length in cm 
 
To check the quality of nucleic acid the ratio of absorbance in different wavelength was 
estimated. A ratio 260/280 of ~1.8 indicates good quality of DNA while a ratio of ~2.0 
indicates “pure” RNA. If the ratio is appreciably lower in either case, it may indicate the 
presence of protein, phenol or other contaminants that absorb strongly at or near 280 nm. The 
260/230 ratio is a secondary measure of nucleic acid purity. It is commonly in the range of 
1.8-2.2. If the ratio is appreciably lower, this may indicate the presence of co-purified 
contaminants. 
4.2.1.10.2 OD600 of bacterial culture 
To monitor growth rate of bacterial cultures, the optical density (OD) of the culture in growth 
media was measured. The OD600 application measures light transmission and uses that value 
to calculate absorbance at 600 nm wavelength. The 1 cm plastic cuvettes were used for 
OD600 measurements. 
4.2.2 Cell culture 
All procedures with cell cultures were performed in sterile conditions under cabinet sterile 
with UV light. All media and other materials were disinfected with 70% ethanol before put 
them under cabinet. Media were also heated for at least 30 minutes in water bath at 37C. 
Cells were cultured in flasks (T25 or T75) and on plates (24-well, 6-well, 6 cm, 10 cm) under 
conducive conditions in incubator (37C, 5% CO2, and 95% of humidity). Media were 
changed daily or every second day. Each time cells were washed with PBS.   




To avoid overgrowth of cultures, cells were passaged when confluence was near 90-100%. 
Cells were washed with DPBS and incubated in minimal amount of trypsin at 37°C until the 
cells detached from the bottom of the culture flask (checked under microscope). Then equal 
volume of medium was added to inactivate enzyme. Cell suspension was transferred to 15 ml 
falcon and then centrifuged for 5 minutes at 1000 rpm. Supernatant was sucked out and cells 
were resuspended in fresh medium, and put into new flasks or on new plates. 
4.2.2.2 Counting  
To obtained particular number of cells in culture, the counting of cells in was performed. 10 
µl of cell suspension was loaded onto Neubauer chamber. Cells were counted in four squares 
of chamber and then the number of cells was estimated with use of equation: 
𝑥
4
× 104 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙 
4.2.2.3 Cryopreservation 
 Cells were grown to a confluency of > 80%, washed with DPBS, and trypsinised. Cell 
suspension was transferred to 15 ml falcon and then centrifuged for 5 minutes at 1000 rpm. 
Supernatant was sucked out and cells were resuspended in fresh medium. The same volume of 
freezing medium was added and cell suspension was aliquoted to cryotubes (1 ml in each). 
Cryotubes were well closed and placed in freezing container. Cells’ stocks were stored in 
freezing container for 24 hours at -80C and transferred for longer storage to -150C. 
4.2.2.4 Feeder layer preparation 
Inactivated mouse embryonic fibroblasts (MEFs) were used as a feeder layer for embryonic 
stem (ES) cells culture. MEF was cultured under normal conditions till 24 T75 flasks were 
fully confluent. Then, cells were incubated with Mitomycin C (10 µg/ml) for 3 hours under 
normal culture conditions. Cells were washed three times with PBS and 72 stocks were frozen 
and stored at -150C.  
4.2.2.5 Transfection of cells 
Transfection was performed with Lipofectamine
™
 2000 Reagent. 24 hours before transfection 
appropriate number of cells were sowed on plates (see Table 29). Transfection complex was 
prepared according manufacture protocol (see Table 29). Briefly, nucleic acid solution and 
Lipofectamine
™
 2000 solution were mixed with Opti-MEM
®
 I Reduced Serum Medium in 
two separate transfection tubes. Both solutions were mixed gently by shaking and incubated 
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for 5 minutes at room temperature. Nucleic acid solution was added to the Lipofectamine
™
 
2000 solution and mixed gently by shaking. Transfection mixture was incubated for 20 
minutes at room temperature to obtain nucleic acid-Lipofectamine
™
 2000 complexes. 
Meantime, culture medium was exchanged to Opti-MEM
®
 (heated to 37C). Transfection 
complex was added to cells (see Table 29) and plates were incubated for 4 hours at 37C. 
Transfection solution was exchanged to normal culture medium. 24-48 hours after 
transfection cells were proceeded for other experiments. 
 
Table 29: Standard Lipofectamine
™



















6-well 5 x 10
5 
4,0 µg 10 µl 250 µl 2 ml 
24-well 5 x 10
4 



















6-well 3 x 10
5 
100 pmoli 5 µl 250 µl 2 ml 
 
4.2.2.6 Immunostaining of cells 
For staining, cells were culture in 24-well plates on glass cover slips. Before staining, cells 
were counted and seated on plates and/or transfected. Culture medium was removed from 
wells and cells were washed two times with pre-warmed PBS (37ºC). Fixation was performed 
using of 4% paraformaldehyd (PFA) in PBS (pre-warmed at 37ºC) for 30 minutes at room 
temperature. Cells were washed again two times with PBS (from this step room temperature) 
and blocked with 50mM NH4Cl for 10 minutes. Then two washings in PBS were performed. 
Permabilization of cell membrane was done by incubation three times for 4 minutes with 
0,2% Triton X-100 in PBS. Then cells were incubated with primary antibody (diluted 1:100 in 
0,2% Triton X-100) for 1 hour at room temperature in staining chamber. Cells were washed 
with 0,2% Triton X-100 three times for 4 minutes and incubated with secondary antibody 
(diluted 1:300 in 0,2% Triton X-100) for 1 hour at room temperature in staining chamber. 
Afterwards the cells were washed with 0,2% Triton X-100 three times for 4 minutes and two 
times with PBS for 5 minutes (all washings were performed in the dark to avoid loss of 
fluorescent signal). ProLong™ Diamond Antifade Mountant with DAPI was dropped onto a 
slide and covered by coverslip with cells. Slides were left for 24 hours at room temperature to 
allow DAPI mountant medium to polymerize. Slides were stored at 4ºC.  
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4.2.2.7 Bimolecular Fluorescence Complementation (BiFC) assay 
The Gateway® cloning resulted in generation of numerous expression plasmids with different 
combinations of fused proteins: 
 pCSDest C-VC – C-terminal part of fluorescent Venus protein linked to the C-
terminus of protein of interest 
 pCSDest C-VN – N-terminal part of fluorescent Venus protein linked to the C-
terminus of protein of interest 
 pCSDest N-VC – C-terminal part of fluorescent Venus protein linked to the N-
terminus of protein of interest 
 pCSDest N-NC – N-terminal part of fluorescent Venus protein linked to the N-
terminus of protein of interest 
Subsequently HeLa cells were co-transfected with NARF, NARFp.H367R, LMNA, CBX5 in 
all possible combinations to evaluate direct interactions between mentioned proteins. 
Subsequently, cells were fixed with 4% PFA 24 hours after transfection. ProLong™ Diamond 
Antifade Mountant with DAPI was dropped onto a slide and covered by coverslip with cells. 
Slides were left for 24 hours at room temperature to allow DAPI mountant medium to 
polymerize. Slides were stored at 4ºC.   
4.2.2.8 Stress experiment 
24 hours before experiment, cells were counted and 4 x 10
5 
cells were seated on 6 cm plate. 
The next day cells were treated with etoposide or UV light. Cells treated with etoposide were 
washed with 2 ml of PBS and incubated with 50 µM etoposide in 3 ml of normal culture 
medium for 1 hour under conducive conditions in incubator. Afterwards, cells were washed 
with 2 ml of PBS and medium was changed to normal culture medium. Cells treated with UV 
light were placed in the UV crosslinker device without lids and treated with UV-C radiation 
with an energy of 10 mJ/cm
2
. Cells were washed with 2 ml of PBS and medium was changed 
to normal culture medium. Cells for protein analysis were harvested by trypsinization 1, 6 and 
24 hours after treatment. Cells pellet were proceeded for total protein extraction immediately 
or stored at -80ºC. Cells for staining were fixed with 4% paraformaldehyde 1, 6 and 24 hours 
after treatment and proceeded with immunostaining immediately or stored in PBS at 4ºC. For 
both analyses proper negative, untreated controls were prepared. 
4.2.2.9 Oxidative stress experiment 
Staining procedure was performed using CellROX
®
 Deep Red Flow Cytometry Assay Kit. 
Cells were collected and the concentration of cells was adjusted to 5x10
5
 cells/ml of growth 
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medium. For each cell line appropriate positive and negative controls were prepared (see 
Table 30). 
Table 30: List of samples prepared for oxidative stress experiment. 




































+ – – + 
Positive control, 
double stained 
+ – + + 
   
Reactive oxygen species (ROS) generation in cells was induced with tert-butyl hydroperoxide 
(TBHP) treatment. Cells were incubated with 200 µM TBHP for 1 hour at 37 ºC. The 
negative control was treated with antioxidant before ROS production induction. Cells were 
incubated with 250-1000 µM N-acetylcysteine (NAC) for 1 hour at 37 ºC before THBP 
treatment. To visualize ROS production in cells, they were subsequently stained with 500 nM 
CellROX
®
 Deep Red for 1 hour at 37 ºC. To visualize dead cells in suspension 1 µM of 
SYTOX
®
 Blue Dead Cell stain was added at the final 15 minutes of staining. The samples 
were analyzed with flow cytometry, using 405-nm and 635-nm excitation for SYTOX
®
 Blue 
Dead Cell stain and CellROX
®
 Deep Red reagent, respectively. Fluorescence emission was 
analyzed with 450/50 BP and 665/40 BP filters for SYTOX
®
 Blue Dead Cell stain and 
CellROX
®
 Deep Red detection reagent, respectively. Untreated, unstained controls were used 
to adjust forward versus side scatter (FSC vs SSC) gating to identify cells of interest. Positive 
single stained controls were used as single-color compensation controls.  
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4.2.2.10  Proliferation assay 
Proliferation assay was performed using CellTiter 96
®
 AQueous One Solution Reagent. It is a 
colorimetric method that allows for determining the number of viable cells. CellTiter 96
®
 
AQueous One Solution Reagent contains the MTS tetrazolium compound which is bioreduced 
by cells, and phenazine ethosulfate (PES) that is electron coupling reagent enhancing 
chemical stability. Cells reduce MTS tetrazolium into colored formazan product which 
quantity can be measured by absorbance. Cells were collected and seeded in 24-well plates, at 
the number of 1,5 x 10
4
, in six repeats. Next day, 100 µl of CellTiter 96
®
 AQueous One 
Solution Reagent was added to each well and cells were incubated for 3 hours under normal 
culture conditions. The quantity of formazan product reflecting the number of living cells was 
estimated by measuring of absorbance at 490 nm with NanoDrop™ OneC Spectrophotometer. 
The measurement was repeated after additional 24 hours and relative change of living cells 
number was estimated by relative change in absorbance. 
4.2.3 Protein analyses 
4.2.3.1 Protein Extraction 
4.2.3.1.1 Protein fractionation using NE-PER Nuclear and Cytoplasmic Extraction 
Reagents 
Cells were collected with trypsinization and pellets were washed with PBS. For nuclear and 
cytoplasmic fractionation cells’ pellets were proceeded immediately and the volume ratio of 
reagents Cytoplasmic Extraction Reagent I (CER I):Cytoplasmic Extraction Reagent II (CER 
II):Nuclear Extraction Reagent (NER) was maintained according to manufacturer’s protocol. 
Reagents CER I and NER were pre-mixed with protease inhibitor cocktail. Cells’ pellets were 
resuspended in ice-cold CER I by vigorous vortexing for 15 seconds and incubated 10 
minutes on ice. Ice-cold CER II was added and samples were vortexed for 5 seconds, 
incubated for 1 minute on ice and vortexed for 5 seconds again. Samples were centrifuged at 
4ºC for 5 minutes at 14800 rpm and cytoplasmic extract was transferred to fresh pre-chilled 
tube. Remained pellets were resuspended in ice-cold NER. Samples were vortexed for 15 
seconds and incubated for 40 minutes on ice with 15 seconds vortexing every 10 minutes. 
Samples were centrifuged at 4ºC for 10 minutes at 14800 rpm and nuclear extract was 
transferred to fresh pre-chilled tube. Depending on the type of experiment, the remaining 
pellets were discarded or subjected to extraction of remained insoluble proteins. Protein 
extracts were stored at -80ºC. 
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4.2.3.1.2 Total protein extraction 
Cells were collected by trypsinization and washed with PBS. The cells’ pellet were proceeded 
immediately or stored at -80ºC. The cell pellets were suspended in 200 µl of Pierce™ RIPA 
Buffer containing protease and phosphatase inhibitors. Cell suspension was sonicated three 
times for 10 periods using microtip, power output 3 and duty cycle 30%. Samples were 
centrifuged at 4ºC for 20 minutes at 13000 rpm. Supernatant was transferred to fresh pre-
chilled tube. Protein extracts were stored at -80ºC.  
4.2.3.2 Measurement of protein concentration using Pierce™ BCA Protein Assay Kit 
This assay allows for the colorimetric detection and quantitation of total protein. To prepare 
samples for measuring 10 µl of protein were mixed with 200 µl of BCA Working Reagent 
(WR). WR was previously prepared by mixing 50 parts of BCA Reagent A with 1 part of 
BCA Reagent B. 200 µl of WR without protein was used as blank sample. Samples were 
mixed and incubated for 30 minutes at 37ºC. Subsequently, samples were transferred to 
special plastic cuvettes and absorbance was measured at 562 nm wavelength using 
NanoDrop™ One
C
. Protein concentration was estimated based on a previously plotted 
standard curve defined by known albumin (BSA) concentrations. 
4.2.3.3 Western blot 
4.2.3.3.1 SDS-PAGE electrophoresis 
To prepare samples required amount of protein, they were mixed with water to obtain the 
equal volume of all samples. Samples were mixed with 4X Laemmli Sample Buffer and 10X 
Reducing Agent (RA), and incubated for 5 minutes at 95ºC in order to denaturate proteins. 
Samples were chilled on ice for 5 minutes and centrifuged briefly. Meantime, the gel in the 
chamber was prepared according manufactural instruction. Samples and 10 µl of Precision 
Plus Protein™ All Blue Standards were loaded onto gel. Electrophoresis was conducted at 
80V till all samples leave wells and then at 120V until the dye reaches the reference line on 
the bottom of cassettes. Gel was removed from cassette and prepared for transfer. Before 
transfer, gel picture of proteins was taken. 
4.2.3.3.2 Transfer on membrane 
Transfer of proteins was performed using Trans-Blot
® 
Turbo™ Transfer System and RTA 
Transfer Kit (Mini, PVDF). For activation PVDF membrane was immersed in 100% 
methanol, washed with water and then equilibrated for 2-3 minutes in cold transfer buffer. 
Transfer stacks were immersed in transfer buffer as well. Next all components were placed in 
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the cassette as a “sandwich” in the following order: bottom wetted stack, equilibrated 
membrane, gel, top wetted stack. Air bubbles and excess buffer were removed with roller. 
Cassette was locked and inserted in the instrument. Transfer was conducted with one of Bio-
Rad preprogrammed protocols – MIXED MW (1,3 A constant for 1 Mini gel or 2,5 A 
constant for 2 Mini gels; up to 25 V; 7 minutes). Membranes were immediately proceeded to 
probing and developing. 
4.2.3.3.3 Probing and developing 
To avoid unspecific binding of antibodies, membrane was blocked by incubation with 5% 
milk in TBST for 1 hour. Membrane was probed with primary antibody diluted 1:1000 in 2% 
milk in TBST overnight at 4ºC, and additional 1 hour at room temperature. Membrane was 
washed three times for 20 minutes with 2% milk in TBST, and then incubated with secondary 
antibody diluted 1:10000 in 2% milk in TBST for 1 hour at room temperature. To remove 
unbound antibodies next series of washing was applied – three times for 20 minutes in 2% 
milk in TBST and three times for 10 minutes in PBS. To detect signal Clarity™ Western ECL 
Substrates and ChemiDoc™ Touch Imaging System were used. 
4.2.3.3.4 Probing and developing – His-tag 
This protocol was used for detection of recombinant His-tagged proteins. After transfer, 
membrane was washed two times for 10 minutes with TBS and blocked with 3% BSA in TBS 
for 1 hour at room temperature. Membrane was washed two times for 10 minutes with 0,05% 
Tween 20 and 0,2% Triton X-100 in TBS, and one time for 10 minutes with TBS. Membrane 
was probed with His-tag antibody diluted 1:1000 in 3% BSA in TBS overnight at 4ºC, and 
additional 1 hour at room temperature. Membrane was washed two times for 10 minutes with 
0,05% Tween 20 and 0,2% Triton X-100 in TBS, and one time for 10 minutes with TBS. 
Membrane was incubated with secondary antibody diluted 1:10000 in 2% milk in TBST for 1 
hour at room temperature. To remove unbound antibodies next series of washing was applied 
– three times for 20 minutes in 2% milk in TBST and three times for 10 minutes in PBS. To 
detect signal Clarity™ Western ECL Substrates and ChemiDoc™ Touch Imaging System 
were used. 
4.2.3.3.5 Stripping and reprobing 
To reprobe membrane with different antibodies, first antibody was removed from membrane 
using Restore™ Plus Western Blot Stripping Buffer. After developing, membrane was 
washed with PBS, and incubated with stripping buffer for 15 minutes at room temperature. 
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Then membrane was washed with TBST and blocked with 5% milk in TBST for 1 hour at 
room temperature. Membrane was reprobed with primary antibody and all steps were 
performed in the same way as for the first development. 
4.2.3.4 Co-immunoprecipitation using Immunoprecipitation Kit Dynabeads® Protein 
G 
Co-immunoprecipitation (CoIP) method was used to study interaction between two proteins. 
For each reaction 50 µl of Dynabeads
®
 was used. Beads were properly resuspended, 
transferred to fresh 1,5 ml tube and supernatant was removed using magnet. To bind antibody, 
beads were incubated with 10 µg of antibody diluted in 200 µl of Ab Binding & Washing 
Buffer. Incubation was carried out with rotation for 10 minutes at room temperature, and then 
overnight at 4ºC. Antibody solution was removed and beads were washed once with 200 µl of 
Ab Binding & Washing Buffer. Beads-antibody complexes were incubated with protein 
extracts obtained from cells (10 µl of extracts were stored at -80ºC as input for further 
analysis). Incubation was carried out with rotation for 10 minutes at room temperature, and 
then overnight at 4ºC. Supernatant was transferred to fresh tube and stored at -80ºC for further 
analysis. Beads were washed three times with 200 µl of Washing Buffer, resuspended in 100 
µl of Washing Buffer and transferred to fresh tube to avoid elution of proteins attached to tube 
wall. Supernatant was removed and beads were resuspended in 20 µl of Elution Buffer and 
10,5 µl of pre-mixed Laemmli Sample Buffer and Reducing Agent (prepared according 
manufacturer’s instruction). Beads-antibody-proteins complexes were eluted and denaturated 
for 10 minutes at 70ºC. CoIP elutions and inputs were loaded on gel and proceeded with 
Western Blot protocol.  
4.2.3.5 Pull-down assay 
For poorly expressed and hardly soluble proteins for which CoIP was not possible, a pull-
down interaction analysis using recombinant proteins was performed. 
4.2.3.5.1 Preparing of chemically competent E. coli BL21 Star™ (DE3) One Shot® cells 
Chemically competent cells were prepared as previously described (see 2.2.1.9.6 Preparation 
of chemically competent E. coli Top10 F’ cells). 
4.2.3.5.2 Recombinant protein expression in BL21 Star™ (DE3) One Shot® bacteria 
For production of recombinant proteins, ORFs of genes of interests were cloned into pET28 
a(+) vector. DNA was introduced into bacterial cells with basic transformation procedure. 
Briefly, bacterial stock was thawed on ice and 10 ng of plasmid DNA was added and mixed 
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without pipetting. Bacteria were incubated for 30 minutes on ice and then heat shocked for 30 
seconds at 42C. Bacteria were chilled on ice for 5 minutes and 250 µl of LB medium were 
added. Bacteria were incubated for 1 hour at 37C with shaking at 600 rpm. 60 µl of bacterial 
suspension was inoculated on LB plates containing ampicillin and incubated overnight at 
37C. One colony was picked with toothpick and incubated in 10 ml of 2x YT medium 
containing ampicillin overnight at 37C with shaking at 160 rpm. The next day, pre-culture 
was inoculated in 500 ml of fresh 2x YT medium containing ampicillin and incubated at 37C 
with shaking at 160 rpm until OD600 reached ~0,4. Bacterial cultures were induced by adding 
IPTG to a final concentration of 0,5 mM and incubation for 3 hours at room temperature with 
shaking. Induced bacteria were collected by centrifugation at 4C for 10 minutes at 4700 rpm. 
To release proteins, bacterial pellets were resuspended in 10 ml of Equilibration/Wash Buffer 
(see 1.2.12.5.3 Purification of recombinant proteins using HisPur™ Cobalt Resin) containing 
protease inhibitor cocktail and sonicated three times for 1 minute on ice using flat tip, power 
output 8 and duty cycle 30%. Samples were centrifuged at 4C for 20 minutes at 14800 rpm 
and supernatant was collected in fresh 15 ml falcon and stored at -80C and proceeded with 
HisPur™ Cobalt Resin purification.  
4.2.3.5.3 Purification of recombinant proteins using HisPur™ Cobalt Resin 
To purify His-tagged proteins expressed in BL21 Star™ (DE3) One Shot® bacteria procedure 
using gravity-flow column and native conditions was used. Columns were packed with 1 ml 
of cobalt resin and left to remove storage buffer by gravity flow. Columns were equilibrated 
with 2 ml of Equilibration/Wash Buffer. 10 ml of bacterial protein extract in 
Equilibration/Wash Buffer was loaded onto the resin and the flow-through was collected in 
fresh 15 ml falcon. Resin was washed two times with 2 ml of Equilibration/Wash Buffer. To 
elute His-tagged proteins, the resin was washed with 4 ml of Elution Buffer and flow-through 
was collected in fresh 1,5 ml tubes – 500 µl each (elution 1-8). All elution samples were 
checked by Western blot. For further analysis proteins were concentrated in smaller amount 
using Centrisart
®
 I (20,000 MWCO CTA) ultrafiltration spin columns. Centrifugation was 
performed few times at 4C for 10 minutes at 2000 rpm till volume reached about 500 µl. 
Protein extracts were stored at -80C. The cobalt resins were reused several times. For that 
purpose, they were regenerated by washing with 10 ml of MES Buffer and 10 ml of ultrapure 
water. The resins were stored as 50% slurry in 20% ethanol at 4C. 
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4.2.3.5.4 Pull-down  
The concentrated His-tagged recombinant proteins were mixed with nuclear or cytoplasmic 
protein fraction extracted from transfected or untransfected cells. Mixture was incubated 
overnight at 4C on roller. His-tagged proteins together with bounded interaction partners 
were purified on HisPur™ Cobalt Resin using the same gravity-flow and native conditions 
procedure. 10-20 µl of each protein extract were left as input control. Pull-down of interacting 
proteins was analyzed by Western blot.  
4.2.4 Knock-in mouse model generation 
4.2.4.1 Preparation of cells for blastocyst injection 
4-5 days prior to injection cells were plated onto gelatinized T75 flasks containing feeder layer 
(mitomycin C-treated MEFs) to obtain appropriate number of cells. 1-2 days prior to injection 
cells were passaged to get consistent density of dividing cells. On the day of injection, 3-4 
hours before trypsinization, the culture medium was changed. Cells were washed with PBS 
and trypsin was added. Trypsinization was performed 10-15 minutes at 37C to obtained 
single cell suspension (checked under microscope). Equal volume of medium was added to 
inactivate trypsin and cells were pipetted up and down to disrupt clumps. Next, cells were 
transferred to 15 ml falcons and centrifuged for 5 minutes at 1000 rpm. Cells were 
resuspended in 10 ml of ES medium and seeded on gelatinized 10 cm plates for 20 minutes to 
remove feeder cells. Then, cells were collected again in 15 ml and centrifuged for 5 minutes 
at 1000 rpm. Cells pellet was resuspended in 1 ml of ES medium containing 20 mM of 
HEPES. Cells were transferred on ice to Max Planck Institute of Experimental Medicine 
(Göttingen), where procedure of blastocyst injection was performed.  
4.2.5 Yeast complementation experiments 
All yeast experiments were performed in collaboration with Prof. Blanche Schwappach lab at 
the Department of Molecular Biology (UMG). All materials and instruments were provided 
by Prof. Schwappach lab, and all procedures were performed with kind help of Àkos Farkas 
and Ariane Wolf.  
4.2.5.1 Yeast transformation (quick and dirty, PEG-LiAc method) 
Day before transformation, yeast strains were inoculated for overnight culture to obtain cells 
in logarithmic phase and increase transformation efficiency. Cells were centrifuged for 1 
minute at 1500 x g and resuspended in 120 µl of LiAc mix. Next, 200-300 ng of plasmid 
DNA, 14 µl of carrier DNA and 750 µl of PEG mix were added. Mixture was mixed and 
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yeasts were incubated 1 hour at 42C. Cells were centrifuged for 1 minute at 3000 rpm, and 
supernatant was discarded. Cells were resuspended in 50-100 µl of autoclaved water. 
Subsequently, yeasts were inoculated on selective plates in decreasing concentrations. Plates 
were incubated at least 2 days in different temperatures, and the ability of protein of interest to 
complement was analyzed by presence or lack of growing yeast cells.   
4.2.6 Statistics analyzes 
Generated data were analyzed using Microsoft Excel. The two-tailed student’s t test was used 







5.1 Identification of novel progeria-associated gene 
Recently, our group studied a 4½-year-old girl diagnosed with a congenital, segmental 
progeria syndrome. She presented with developmental delay, intellectual disability, mild 
primary microcephaly, short stature, dilated cardiomyopathy, reduced subcutaneous fat, 
wrinkly skin and sparse hair, and a progeroid facial expression. She showed no recurrent 
infections or any other signs of immunological problems. The clinical observations were in 
accordance with the diagnosis of a progeroid syndrome, with an early onset in the first years 
of life, partially resembling the Cockayne syndrome. We performed trio whole-exome 
sequencing (WES) on DNA extracted from blood lymphocytes of the patient and her parents. 
Using an in-house analysis pipeline established by our research group, we conducted WES 
data analysis and in addition filtering of variants with the Varbank platform (varbank.ccg.uni-
koeln.de). We applied the following criteria for the filtering of the WES variants: coverage of 
over ten reads, a minimum quality score of 10, allele frequency ≥ 20%, and a minor allele 
frequency (MAF) < 0.000001 in the ExAC database. Using these filter criteria, we found that 
WES revealed only one variant, which was present in the patient but not in both parents. This 
variant was located in the Nuclear Prelamin A Recognition Factor (NARF) gene, and de novo 
occurrence was confirmed through Sanger sequencing (Figure 5a). The c.1100A>G mutation 
converts a highly conserved histidine at position 367 to arginine (p.His367Arg; Figure 5b) 
and is predicted to be damaging by several prediction programs, including MutationTaster, 
PolyPhen2, PROVEAN, and SIFT. At the start of my thesis, NARF function was only poorly 
characterised. NARF was shown to interact with pre-lamin A in a farnesylated manner 
(Barton and Worman, 1999). As mutations in Lamin A (LMNA) lead to HGPS, the most 
prominent premature ageing disorder, we considered the p.His367Arg mutation in NARF 
highly relevant, and we considered NARF a promising candidate gene regarding the observed 
phenotype in the patient (Schotik, 2017). In addition to this hypothesis, patient-derived 
fibroblasts exhibited an abnormal nuclear structure presented by increased blebbing of the 
nuclear lamina (data not shown; Schotik, 2017). Interestingly, in C. elegans’s mutant oxy-4, a 
missense mutation in the identical region induced increased sensitivity to oxidative stress and 





Figure 5: Identification of a de novo mutation in NARF in a patient with a progeroid syndrome phenotype. 
(a) Chromatograms illustrating the de novo mutation c.1100G>A in NARF. (b) Cross-species alignment 
depicting conservation of the p.H367 residue (boxed in black) affected by the identified c.1100A>G mutation. 
(c) Cross-species alignment illustrating conserved region of mutation (boxed in black) in human and C. elegans. 
  
5.2 Anti-NARF/Narf antibody generation 
Antibodies are essential research tools that have enabled researchers from various fields of 
science to identify, locate, and quantify protein targets. Since commercially available anti-
NARF antibodies were unspecific or inefficient, I decided to generate a new antibody 
recognising both human and mouse NARF/Narf proteins for further functional in vitro and in 
vivo studies. I developed an anti-NARF/Narf (further referred to as anti-NARF) antibody in 











collaboration with the Eurogentec company. The strategy was based on the immunisation of 
animals with two different 16-amino-acid peptides (peptide A and peptide B), which were 
common for mouse and human proteins without any homology for other proteins. To increase 
the chance of generating a specific antibody, we used two host species: rabbit and llama. We 
immunised two rabbits and two llamas. We injected one animal in each pair with peptide A 
and the other with peptide B, culminating in the generation of four anti-NARF antibodies. I 
further tested the specificity of the generated antibodies on protein extracts from HeLa cells. 
Protein extracts from NARF-overexpressing HeLa cells served as a control. To analyse the 
subcellular localisation of NARF, I split the protein extracts into cytosolic and nuclear 
fractions. Western blot (WB) analysis revealed that the peptide-A-derived antibodies, both 
rabbit and llama, were unspecific, resulting in the appearance of several bands (data not 
shown). We thus excluded these two antibodies from further studies. By contrast, the peptide-
B-derived antibodies showed specificity for two proteins: the exogenous overexpressed Myc-
NARF protein (upper band ~52 kDa) and a smaller protein (lower band ~42 kDa) that was 
present in both, the cytoplasmic and nuclear protein fractions, independent of NARF 
transfection, showing the endogenous origin of this protein (Figure 6a). To test whether the 
lower band corresponded to endogenous NARF, I performed a knock-down (KD) assay using 
small interfering ribonucleic acid (siRNA) transfection in the HeLa and HEK293T cells. 
Quantitative real-time PCR (qRT-PCR) analysis demonstrated that siRNA transfection with 
two different siRNAs or a combination thereof reduced the expression of the NARF gene to 
~10-20% and ~40-60% in the HeLa and HEK293T cell lines, respectively (Figure 6b). 
Transfection with scrambled siRNAs (Ctrl) served as a control. WB analysis performed on the 
total proteins extracted from both cell lines showed no difference between the NARF siRNA 
and Ctrl siRNA treated cells in terms of the 42 kDa band intensity (Figure 6c), which did not 
decrease, indicating that the recognised protein was not the endogenous NARF. On testing 
proteins extracted from WT and Narf KD mouse NIH 3T3 cells, I obtained similar results 
(data not shown). To further characterise the affinity of the produced antibodies, I performed 
immune precipitation (IP) assays in HeLa cells, using the rabbit antibody, followed by 
proteomic analysis. Rabbit IgG IP served as a negative control (Figure 6d). I used the gel 
fragment containing the proteins separated with SDS-PAGE (proteins corresponding to 28-
62kDa; Figure 6d, red frame) for mass spectrometry analysis performed by the Proteomics 
Service Facility, Göttingen. Proteomics analysis revealed that the generated antibody 
exhibited high affinity to β-actin (1030 reads) but only minor affinity to endogenous NARF 




NARF (~52 kDa), but it exhibited a much higher affinity to β-actin in the protein extracts 
from HeLa cells. 
 
Figure 6: Generation of antibodies against mouse/human NARF protein. (a) Western blot analysis showing 
the specificity of the generated llama anti-NARF antibodies. The tested antibody recognised the exogenous 
overexpressed Myc-tagged NARF (upper band ~52 kDa) and a smaller endogenous protein (lower band ~42 
kDa) in protein lysate extracted from NARF-overexpressing and WT HeLa cells. (b) qRT-PCR results 
demonstrating the efficiency of siRNA knock-down (KD) of NARF in HeLa and HEK293T cells. siRNA 
transfection reduced the expression of NARF to ~10-20% and ~40-60% in the HeLa and HEK293T cell lines, 
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siRNA KD exerts no effect on the expression of the endogenous protein detected by the tested antibody. Cells 
treated with siRNA against NARF and the cells treated with scrambled siRNA were comparable in terms of the 
intensity of the signal. (d) Results of the immunoprecipitation (IP) assay performed with either the tested rabbit 
anti-NARF (left column) or anti-rabbit IgG (right column) antibodies on the protein lysate from the HeLa cells. 
The red box represents the gel fragments used for proteomics analysis. (e) The list of the proteins detected in the 
rabbit anti-NARF IP. The most abundant protein detected by the rabbit anti-NARF antibody was β-actin (1030 
hits). NARF itself was also detected with the IP fraction, albeit with extremely low efficiency (4 hits). M1 = 
SeeBlue Plus2 Pre-Stained Protein Standard, M2 = Precision Plus Protein™ All Blue Pre-Stained Protein 
Standards. 
 
5.3 Effect of the p.His367Arg mutation on the cellular localisation of 
NARF 
The nuclear localisation of the NARF protein has been previously described (Barton and 
Worman, 1999). To validate this and to analyse the impact of the p.His367Arg mutation on 
protein localisation, I generated expression plasmids for wild-type (further referred as NARF 
WT) and mutant (further referred as NARF
p.H367R
) NARF, both N-terminally tagged with a 
Myc-tag. I transfected HeLa cells with these expression constructs to overexpress WT or 
mutant NARF. Subsequently, I subjected the transfected cells to immunostaining with anti-
Myc antibodies, and I analysed the subcellular localisation of NARF using fluorescence 
microscopy. Expression of Myc-tagged NARF WT in the HeLa cells resulted exclusively in a 
nuclear localisation, mainly co-localising with the nuclear envelop. By contrast, Myc-tagged 
NARF
p.H367R
 was primarily present in the cytoplasm of the transfected cells, and it was no 
longer translocated to the nucleus as observed for NARF WT. In addition, NARF
p.H367R
 was 
not evenly distributed in the cytoplasm, but aggregated within the cytoplasm, forming puncta 
and clump-like structures (Figure 7a). Subsequently, I confirmed these results independently 
through WB analyses. I subjected the proteins extracted from the HeLa cells overexpressing 
either NARF WT or NARF
p.H367R
 to subcellular fractionation, and I isolated the cytoplasmic 
and nuclear fractions of the proteins and subjected them to WB analysis using anti-Myc-tag 
antibodies. I found that NARF WT was present in both the cytoplasmic and the nuclear 
fractions extracted from the HeLa cells, but I only detected NARF
p.H367R
 in the cytoplasmic 







Figure 7: Cellular localisation of overexpressed WT NARF and mutant NARF
p.H367R 
proteins. (a) 
Immunofluorescence staining with the anti-Myc-tag antibodies (green) revealed expression of Myc-tagged WT 
NARF in the nucleus and expression of mutant Myc-tagged NARF
p.H367R
 in the cytoplasm. I used DAPI (blue) 
and phalloidin (red) staining to stain the DNA and to show the shapes of the cells, respectively. NARF WT was 
localised in the nucleus, mostly on the nuclear envelope, while mutant NARF
p.H367R
 was expressed in the 
cytoplasm and accumulated in aggregates. Scale bars = 10 µm. (b) Western blot analysis depicting the cellular 
distribution of the overexpressed WT NARF and mutant NARF
p.H367R
 proteins. The NARF WT protein was 
present in both fractions, but was predominantly expressed in the nuclear fraction, whereas mutant NARF
p.H367R
 
was expressed exclusively in the cytoplasmic fraction. I used the anti-LMNA/C antibody and anti-α-tubulin as 
nuclear and cytoplasmic fraction controls, respectively. M = SeeBlue Plus2 Pre-Stained Protein Standard, CF = 
cytoplasmic fraction, NF = nuclear fraction. 
 
Interestingly, the expression of NARF
p.H367R
 was always significantly lower than the 
expression of NARF WT. To determine whether the observed differences were attributable to 
inefficient transfection or the instability and degradation of the mutant protein, I transfected 
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HeLa cells with both forms of the NARF protein tagged with Myc-tag. I then extracted the 
cytosolic and nuclear protein fractions from 24, 48, and 72 hours after transfection and 
analysed them through WB using anti-Myc-tag antibodies. The WB analysis indicated that 
NARF WT was equally expressed over time, whereas the expression of mutant NARF 
dramatically decreased 48 hours after transfection. At 72 hours after transfection, 
NARF
p.H367R
 could not be detected in either the lysates (Figure 8). 
 
Figure 8: Stability of WT NARF and mutant NARF
p.H367R
. Western blot results illustrating the expression 
levels of overexpressed WT and mutant NARF 24, 48, and 72 hours after the transfection of HeLa cells with 
pCMV-Myc-N plasmids expressing either NARF WT or NARF
p.H367R
. I detected overexpressed proteins using 
anti-Myc-tag antibodies. The NARF WT protein was expressed 72 hours after transfection, while mutant 
NARF
p.H367R
 was almost undetectable after 48 hours. M = SeeBlue Plus2 Pre-Stained Protein Standard, CF = 
cytoplasmic fraction, NF = nuclear fraction. 
 
The severe effect induced by a single amino acid change in the protein sequence suggested 
that the conserved histidine at position 367 in NARF plays an important role for protein 
function. To further evaluate these findings, I designed a series of mutants, introducing a point 
mutation into the triplet encoding the histidine at position 367; I established six different 
mutant forms of NARF (named mutations 1-6, as enumerated in Table 31). Mutation 6 
represented a negative control for this experiment. This represents a synonymous variant, 
c.1101C>T, not altering the amino acid (p.H367H).  
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Table 31: Amino acid changes in the NARF mutants. List of the mutations introduced into the NARF protein 
at amino acid position 367. The table reports the changes at the cDNA and protein levels and the characteristics 




Type of Amino Acid 
Change 
Mutation 0 – patient’s mutation c.1100A>G p.H367R 
basic > basic 
aromatic > aliphatic 
Mutation 1 c. 1100 A>C p.H367P 
basic > neutral 
aromatic > aliphatic 
Mutation 2 c.1100 A>T p.H367L 
basic > neutral 
aromatic > aliphatic 
Mutation 3 c.1099 C>G p.H367D 
basic > acidic 
aromatic > aliphatic 
Mutation 4 c.1101 C>G p.H367Q 
basic > neutral 
aromatic > aliphatic 
Mutation 5 c.1099 C>T p.H367Y 
basic > neutral 
aromatic > aromatic 
Mutation 6 – negative control c.1101 C>T p.H367H – 
 
I cloned all the mutants’ open reading frames (ORFs; 1-6) into the pCMV-Myc-N vector. 
Next, I transfected HeLa cells with all the constructs and subjected them to immunostaining 
with anti-Myc-tag antibodies. Using fluorescence microscopy, I examined the subcellular 
localisation of all six of the mutants. Like NARF
p.H367R












within aggregates in the cytoplasm of the transfected cells (Figure 9). Meanwhile, the 
negative control represented by a synonymous change (mutation 6, Table 1) was localised in 
the nucleus and  associated with the nuclear envelope, as observed for NARF WT (Figure 9). 
These results substantiated the important role of the histidine at position 367 in the cellular 

















). I employed immunofluorescence 
























NARF mutants were localised in the cytoplasm, while NARF
p.H367H
, which served as the control, was localised in 
the nucleus. I counterstained the nuclei with DAPI (blue). Scale bars = 10 µm. 
 
5.4 Identification of novel NARF interaction partners 
To expand our knowledge regarding the potential function of NARF, I attempted to identify 
novel NARF interaction partners. In collaboration with the Hybrigenics Services, a yeast-two-
hybrid (Y2H) assay was performed. We used full-length NARF as bait and screened 
interactions using human ventricle and embryo heart cDNA libraries. In this assay, we were 
not able to verify interaction with pre-lamin A, which has been previously reported (Barton 
and Worman, 1999). Still, we identified two novel protein interaction partners with very high 
confidence, that is, NARF and CBX5 (HP1-α; Figure 10). The presence of NARF itself 
suggested the formation of homodimers by NARF. The second interaction partner, CBX5, is a 
mammalian heterochromatin protein that interacts with many nuclear proteins, including 
lamins. CBX5 also interacts with lamin A, and it has been associated with premature ageing 







Figure 10: Identification of novel NARF interaction partners using a yeast-two-hybrid (Y2H) screening. 
The summary of the Y2H screening results provided by the Hybrigenics Services. The Y2H screening identified 
two potential interaction partners of NARF: CBX5 and NARF itself (red frames). Based on the global Predicted 
Biological Score (PBS), these interactions were predicted with very high confidence (A in red square). Clone 
names: pB = bait vector; A = prey clone number; Type Seq indicates whether 5p and/or 3p sequences are 
available for prey identification; Start/Stop = position of the 5p and 3p prey fragment ends relative to the 
position of the ATG start codon (A = 0); IF = in frame with the Gal4 Activation Domain; OOF1, OOF2 = out of 
frame; N = antisense orientation with respect to the reference sequence; %Id 5p/3p indicates the % identity of the 
prey fragment sequences with the gene reference sequence; PBS = Predicted Biological Score, which indicates 
the confidence in an interaction; A = very high confidence in the interaction; D = moderate confidence in the 
interaction; E = interactions involving highly connected prey domains, non-specific interactions; N/A = not 
applicable. 
 
To validate the co-localisations of likely interacting proteins, I transfected HeLa cells with 
hEF1α-GFP NARF WT plasmids. Subsequently, I subjected the cells to immunostaining 
using anti-LMNA/C or anti-CBX5 antibodies to define the cellular localisations of 
endogenous lamin A and CBX5, respectively. Using fluorescence microscopy, I confirmed 




nuclear compartment of the transfected cells. Additionally, NARF and lamin A co-localised 
within the nuclear envelope (Figure 11). WB analyses further substantiated these results. I 
subjected protein extracts from the HeLa cells transfected with either Myc-tagged NARF WT 
or Myc-tagged NARF
p.H367R
 to WB analysis and probed the membranes with anti-Myc-tag, 
anti-lamin A/C, and anti-CBX5 antibodies. The results confirmed that NARF WT, but not 
NARF
p.H367R
, co-localises in nuclear protein fractions. I used proteins extracted from non-
transfected HeLa cells as a control; they demonstrated expression of endogenous lamin A and 
CBX5 proteins, but not exogenous NARF-Myc proteins. The presence of mutant NARF
p.H367R
 
exerts no impact on the expression or subcellular distribution of either lamin A or CBX5 
(Figure 12). Both proteins remained present in the nuclear fractions of the cell lysates. 
 
 
Figure 11: Co-localisations of NARF and its interaction partners lamin A and CBX5. Immunofluorescent 
images of HeLa cells transfected with WT NARF-GFP (green). I employed anti-LMNA/C and anti-CBX5 
antibodies to analyse the localisations of endogenous lamin A and CBX5, respectively (red). NARF co-localises 
with both the tested interaction partners within the nucleus. I counterstained the nuclei with DAPI (blue). Scale 
bars = 10 µm. 
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lamin A/C, and CBX5. Western blot 




lamin A and CBX5 in cytosolic and nuclear protein fractions from HeLa cells. The NARF WT protein was 
present in both fractions but was predominantly expressed in the nuclear fraction, while mutant NARF
p.H367R
 was 
expressed exclusively in the cytoplasmic fraction. Lamin A and CBX5 were present only in the nuclear fraction. 
Overexpression of mutant NARF
p.H367R 
altered neither the expression nor the cellular distribution of lamin A and 
CBX5. Protein extracts from non-transfected cells (Ctrl) served as a control. I used the β-actin antibody as a 
control for protein loading. M = Precision Plus Protein™ All Blue Pre-Stained Protein Standards. 
 
To examine the direct interactions between NARF and lamin A, I conducted co-
immunoprecipitation (CoIP) experiments. I transfected HeLa cells with expression constructs 
for Myc-tagged NARF WT; I then extracted proteins and used the nuclear fractions in the 
CoIP experiments. Using magnetic beads conjugated with anti-Myc-tag antibodies and the 
nuclear fractions, I initiated immunoprecipitation (IP) of the proteins. After allowing the IP to 
proceed overnight, I eluted the proteins from the beads, denaturised them, and subjected them 
to WB analysis using anti-LMNA/C antibodies. Since lamin A was co-eluted from the protein 
extracts alongside with Myc-NARF, the results evinced a direct interaction between NARF 
and lamin A. To exclude unspecific binding, I performed the same procedure using beads 
conjugated with mouse IgG as a negative control (Figure 13a). I executed the same CoIP 
procedures to study the direct interactions between NARF and CBX5. Nevertheless, my 
efforts to co-precipitate NARF with CBX5 were unsuccessful (data not shown); I therefore 
decided to switch the methods and to use a pull-down assay to investigate the direct 
interactions between NARF and CBX5. For this purpose, I used cell lysates from HeLa cells 
CF = cytoplasmic fraction 
















overexpressing Myc-tagged NARF proteins; additionally, I used recombinant His-tagged 
CBX5. Recombinant CBX5-His was expressed in the bacterial BL21 strain, and the presence 
of the His-tag enabled purification of both, the CBX5 protein from the bacterial lysates, and 
subsequent purification of the protein complexes. I extracted the nuclear and cytoplasmic 
fractions of the HeLa cells overexpressing NARF WT or NARF
p.H367R
 proteins, and I 
performed a pull-down assay overnight, using the purified recombinant CBX5-His protein 
and the nuclear and cytoplasmic lysates. Using HisPur™ resins, I purified the protein 
complexes again; I then subjected the proteins to WB analysis using anti-Myc-tag antibodies. 
Since NARF was pulled down alongside with CBX5-His, the results confirmed a direct 
interaction. Moreover, this experiment demonstrated that the mutations do not disrupt the 
interaction between NARF and CBX5, as NARF
p.H367R
 retained the ability to bind and be 
pulled down together with CBX5-His (Figure 13b). 
 
Figure 13: NARF interaction partners. (a) Western blot results of the co-immunoprecipitation experiments 
conducted in HeLa cells overexpressing NARF WT. Using the anti-Myc-tag antibody, I performed 
immunoprecipitation of the NARF-lamin A complex in the nuclear fractions; subsequently, I conducted WB 
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control, I performed IP with the IgG antibody. (b) Western blot results of the pull-down experiments conducted 
with the recombinant CBX5-His protein and protein extracts from HeLa cells overexpressing NARF WT and 
NARF
p.H367R
. I incubated the protein extracts with recombinant CBX5-His; subsequently, the protein complexes 
were purified through resins binding the His-tag. I conducted WB analysis of the purified proteins, using anti-
Myc tag antibodies. Both the NARF and NARF
p.H367R
 proteins were pulled down alongside with the recombinant 
CBX5 protein. CF = cytoplasmic fraction, NF = nuclear fraction, M = Precision Plus Protein™ All Blue Pre-
Stained Protein Standards. 
 
To verify the direct interactions between NARF and lamin A as well as CBX5, I designed and 
prepared new expression plasmids for a bimolecular fluorescence complementation (BiFC) 
assay. Briefly, this experiment requires co-transfection of cells with plasmids that express 
potential interaction partners fused to the C- or N-terminal fragment of Venus fluorescent 
protein. Fragments of reporter protein are linked to the C- or N-terminus of the examined 
proteins with flexible linkers that enable reformation of the native structure of the reporter 
protein and emission of a fluorescent signal in the case of direct interactions between the 
tested proteins (Kerppola, 2006). I co-transfected HeLa cells with plasmids expressing NARF 
WT fused to the N-terminal fragment of the reporter Venus protein (VN) and NARF WT, 
lamin A, or CBX5 fused to the C-terminal fragment of the reporter Venus protein (VC), 
respectively. Using fluorescence microscopy, I observed direct NARF-NARF, NARF-lamin 
A, and NARF-CBX5 interactions, which resulted in green fluorescent signals emitted by the 
reconstituted Venus protein (VN + VC) (Figure 14). Taken together, I was able to identify 








Figure 14: Bimolecular fluorescence complementation assay of NARF and its interaction partners. 
Immunofluorescent photographs illustrating the results of the bimolecular fluorescence complementation (BiFC) 
assay testing the direct interactions between NARF WT and its potential interaction partners (NARF, lamin A, 
and CBX5). Interactions between the proteins enabled reconstitution of the Venus protein (VN + VC) and 
emission of fluorescent signals (green). I counterstained the nuclei with DAPI (blue). Scale bars = 10 µm. 
 
5.5 Dominant negative effect of NARFp.H367R 
The impaired cellular localisation of NARF
p.H367R
 and the homodimerisation of NARF raised 
the questions of a possible dominant negative effect of NARF
p.H367R
 on NARF WT. To 
investigate this, I co-transfected HeLa cells with both WT and mutant forms of the NARF 
protein tagged with different tags (Myc or GFP) to distinguish between overexpressed 
proteins. Co-expression of Myc- and GFP-tagged WT proteins resulted in fluorescence 
signals in the nucleus, primarily within the nuclear envelope (Figure 15a). By contrast, co-
expression of WT and mutant proteins still co-localised, but this occurred predominantly 
outside the nucleus (Figure 15b). Similarly, co-expression of GFP- and Myc-tagged mutant 
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proteins also indicated co-localisation exclusively within the cytoplasm of transfected cells 
(Figure 15c).  
To confirm the dominant negative effect of NARF
p.H367R
, I performed a bimolecular 
fluorescence complementation (BiFC) assay. I co-transfected HeLa cells with plasmids 
expressing NARF WT fused to the C-terminal fragment of the reporter Venus protein (VC) 
and the NARF
p.H367R
 protein fused to the N-terminal fragment of the reporter Venus protein 
(VN). As depicted in Figure 15d, mutant NARF
p.H367R
 interacts with WT NARF, but the 







Figure 15: A dominant negative effect of the mutant NARF
p.H367R 
protein. (a) Immunofluorescent analysis of 
the HeLa cells co-transfected with GFP- and Myc-tagged NARF WT (green and red, respectively). The GFP- 
and Myc-tagged NARF WT co-localised at the nuclear envelope. (b) Immunofluorescent analysis of the HeLa 
cells co-transfected with GFP-tagged NARF WT (green) and Myc-tagged NARF
p.H367R
 (red). WT and mutant 
NARF co-localised but were detected primarily in the cytoplasm and only to a minor extent in the nucleus. (c) 
Immunofluorescent analysis of HeLa cells co-transfected with GFP- and Myc-tagged NARF
p.H367R 
 (green and 
red, respectively). The mutant proteins co-localised exclusively outside the nucleus. (d) BiFC assay verifying the 
dominant negative effect of the p.His367Arg mutation. The NARF
p.H367R
 was able to interact with the NARF 
WT, thereby limiting the protein complex localisation to the cytoplasm. I counterstained the nuclei with DAPI 































I demonstrated that the mutation does not disrupt the NARF-NARF interaction; however, 
NARF
p.H367R
 exerts an effect on NARF WT, as it alters its subcellular localisation. The 
obtained results might suggest that the conserved histidine at position 367 possibly plays a 
role in protein complex trafficking and proper localisation.  
5.6 Is NARF function evolutionarily conserved? 
NARF is a highly conserved protein. To analyse whether human NARF, like its yeast 
homologue NAR1, boasts an evolutionarily conserved function, I performed a 
complementation assay in yeast. To this end, I employed a decreased abundance by mRNA 
perturbation (DAmP) Nar1 yeast strain that allows for generating hypomorphic alleles of 
essential yeast genes. Briefly, the 3’ untranslated region (3’UTR) of a gene is disrupted 
through insertion of an antibiotic resistance cassette, which engenders the destabilisation of 
the transcript and the reduction of mRNA levels (Breslow et al., 2008). Because there are two 
Nar1 homologues—that is, NARF and NARFL—in mammals, I implemented cDNA 
encoding for both proteins and tested their ability to rescue the Nar1-deficient phenotype in 
yeast. In a first approach, I cloned yeast codon-optimised ORFs of NARF, NARFL, and NAR1 
into the p415 mTag BFP2 vector. To test the expression of the human proteins in yeast, I 
transformed the WT By4741 yeast strain with p415 mTag BFP2 -NARF, -NARFL, and -Nar1 
plasmids. The transformation of WT yeast resulted in detectable, but low expression of all 
three recombinant proteins in the logarithmic phase of yeast growth. In the stationary phase of 
growth, however, NARF and NARFL aggregated in foci (Figure 16), whereas Nar1 was 





Figure 16: Expression of BFP-tagged Nar1, NARF, and NARFL proteins in the WT By4741 yeast strain. I 
transformed yeast strain By4741 with p415 mTag BFP2 plasmids containing yeast NAR1 and yeast codon-
optimised ORFs of human NARF and NARFL genes. Using fluorescence microscopy, I detected the expressed 
proteins, which were tagged with blue fluorescent protein (BFP2). All three recombinant proteins were equally 
distributed within the cells during the logarithmic phase of yeast growth. In the stationary phase, the human 
NARF and NARFL proteins aggregated in foci. Scale bar = 5 µm. 
 
In a next step, I tested the different culture conditions to find conditions that exert an effect on 
the DAmP Nar1 strain, but are neutral for growing WT yeast. I cultured WT and DAmP Nar1 
yeast strains either at different temperatures or on selective plates supplemented with either 
hydrogen peroxide (H2O2) or copper sulphate (CuSO4). Preliminary experiments have 
indicated that the presence of hydrogen peroxide or copper sulphate, but not a higher 
temperature alone, is able to prevent the DamP Nar1 strain from growing (Figure 17a). I then 
performed a complementation assay on the plates supplemented with hydrogen peroxide. Still, 
none of the tested proteins were able to rescue the DAmP Nar1 phenotype (Figure 17b). 
Neither transformation with yeast Nar1, nor transformation with NARF or NARLF exerted 
any effect on the growth of this DAmP Nar1 strain. This result was observed independent of 
the presence of hydrogen peroxide. The negative results obtained in the experiment with the 
positive control plasmids (p415 mTag BFP2 Nar1) and the observed aggregation of BFP2-
fused human proteins suggest that BFP may jeopardise the proper folding and function of 
5 µm 
By4741 









tagged proteins. To rule out a detrimental impact of BFP2 on the expression of the Nar1, 
NARF, and NARFL proteins, I repeated the complementation assay using the DAmP Nar1 
strain and untagged Nar1, NARF, and NARFL. Again, none of the proteins proved able to 




Figure 17: Complementation assay performed in the DAmP Nar1 yeast strain. (a) Identification of 
conditions that impair the growth of the DAmP Nar1 yeast strain. The growth of DAmP Nar1 is suppressed by 
H2O2 or CuSO4 but not by increased temperature. (b) The growth of DAmP Nar1 can be rescued neither by the 

































In light of these results, I concluded that the DAmP Nar1 strain and the selection conditions 
are not optimal. Therefore, I changed the yeast strains and used the ΔNar1 strain, in which the 
NAR1 gene has been deleted (KO). Because nar1-KO is lethal, I transformed the ΔNar1 yeast 
with the p416 Nar1 plasmid. Expression of Nar1 from this plasmid is driven by the MET25 
promoter. In media lacking methionine, the MET25 promoter induces high expression of 
Nar1, thus enabling normal growth of ΔNar1 yeast (Mumberg et al., 1994). Additionally, the 
p416 plasmid encodes for the URA3 gene. URA3 is an orotidine-5'-phosphate decarboxylase 
(ODCase), which is an enzyme that catalyses one step in the synthesis of pyrimidine 
ribonucleotides (Flynn and Reece, 1999). ODCase can also convert 5-fluororotic acid (5-
FOA) into the toxic compound 5-fluorouracil (Boeke et al., 1984). This allows for selecting 
against yeast carrying the URA3 gene. In the presence of 5-FOA, these cells will die. I applied 
this model to perform a further complementation assay. I transformed ΔNar1-p416 Nar1 yeast 
with p415 plasmids encoding for either Nar1 or its human homologues, NARF and NARFL. I 
then cultured the transformed yeast on 5-FOA selective plates, thereby eliminating cells that 
express Nar1 from the p416 plasmid. This enabled me to test the effect of the transfected 
factors encoded within the p415 plasmid (Nar1, NARF, and NARFL). In the first trial, I 
transformed ΔNar1-p416 Nar1 yeast with p415 encoding for untagged or BFP2-tagged Nar1, 
NARF, or NARFL. In these cases, the Nar1 protein proved able to rescue the growth of the 
ΔNar1 yeast, whereas the yeast transformed with either NARF or NARFL died on undergoing 
the 5-FOA treatment (Figure 18a). In addition, to help stabilise the human proteins and 
possibly improve their folding and/or solubility, I tested another tag: tandem A protein (ZZ-
tag). I obtained similar results: I was only able to rescue the growth of ΔNar1 with the Nar1 
protein (Figure 18b, upper panel). Since the proteins expressed from the p415 were under the 
control of the MET25 promoter, which is sensitive to methionine concentrations, I decreased 
the concentration of methionine in the culture medium from 20 mg/L to 5 mg/L. Nevertheless, 
lowering the methionine concentration exerted no effect on the inability of either human 
NARF or human NARFL to rescue ΔNar1 yeast (Figure 18b, lower panel). Taken together, 
these results indicate that neither NARF nor NARFL is able to rescue ΔNar1 yeast; thus, these 
results suggest that yeast Nar1 fulfils a different functional role than the one fulfilled by 





Figure 18: Complementation assay performed in nar1-KO yeast (ΔNar1). (a) Transformation of nar1-KO 
yeast with untagged or BFP2-tagged Nar1, NARF, or NARFL. NARF and NARFL both proved unable to 
recover the yeast growth. (b) I obtained the same results when I used ZZ-tagged proteins in the presence of 
normal and decreased methionine concentrations. Transformation with yeast Nar1 served as the control. In both 
experiments, the yeast Nar1 protein rescued the ΔNar1 phenotype. SC = Synthetic complete medium. 
 
By4741 nar1Δ::NAT p416 Nar1 + 
SC-Leu + 5-FOA 
By4741 nar1Δ::NAT p416 Nar1 
+ p415 2x ZZ-tag TEV-X 










5.7 Generation of a Narfp.H373R knock-in mouse as a model for the 
progeroid syndrome 
To determine the effect of the identified p.His367Arg mutation in NARF and to analyse 
NARF function in general, I aimed to generate a CRISPR/Cas9-mediated knock-in (KI) 
mouse model. The patient’s mutation corresponds to position 1118 (c.1118A>G, p.His373) in 
exon 10 of Narf, and it converts the histidine at position 373 to arginine (p.His373Arg). To 
introduce this particular mutation into Narf, I used two CRISPR vectors (CRISPR Narf #2 
and CRISPR Narf #3) encoding the essential components for the CRISPR/Cas9 approach, 
such as the guide RNA (gRNA) complement to the target region in exon 10 adjacent to the 
amino acid p.His373, the Cas9 nuclease that provides DNA cutting and formation of double-
strand breaks (DSBs) within the target site, and red fluorescent protein (RFP) for easier 
selection of transfected cells. CRISPR Narf #2 and CRISPR Narf #3 plasmids differ slightly 
in their gRNA sequences, but both target the region within exon 10 near the codon of amino 
acid p.His373. In a preliminary experiment, I validated the specificity and efficiency of the 
provided plasmids. Briefly, I transfected mouse embryonic stem (mES) cell line EDJ #22 with 
CRISPR Narf #2 or CRISPR Narf #3 plasmids. After implementing fluorescence-activated 
cell sorting (FACS), I cultured RFP-positive cells to obtain mES cell colonies. I cultured each 
colony separately to give rise to an mES cell line. In this way, I established 11 and 33 mES 
cell lines after transfection with CRISPR Narf #2 and CRISPR Narf #3, respectively. I 
genotyped each mES cell line through Sanger sequencing. Most of the mES lines presented 
with small ‘indels’ or substitution mutations at the targeted position in exon 10 of Narf (Table 
32), thus demonstrating that the tested CRISPR plasmids efficiently introduced DSBs and 
activated DNA repair mechanisms.  
 
Table 31: List of mutations obtained after CRISPR/Cas9 transfection. Summary of the mutations introduced 
by repairing of DNA double-stranded breaks (DSBs) generated by CRISPR Narf #2 and CRISPR Narf #3. DNA 
changes, corresponding protein changes together with genetic status of each clone are listed in the table. 
EDJ #22 CRISPR Narf #2 
Clone cDNA status Protein status Genetic status 
#1 WT WT WT 


















c.1110-1120 del (TCCCATACCACT) 
p.K366N 
fs*432 




c.1114-end of exon 10? del 
p.372-379 del (YHFVEVLA) 





c.1127 A>G p.E376G 
















fs*378  compound 
heterozygote c. 1117-1118 CA>TT 
c. 1119 del (C) 
p.H373F 
fs*385 
EDJ #22 CRISPR Narf #3 
Clone cDNA status Protein status Genetic status 
#1 WT WT WT 
#3 WT WT WT 
#4 
c.1011 T>A 





c.1024 A>G p.N342D 
#5 WT WT WT 
#7 WT WT WT 







p.368-375 del (GKLPYHFV) 
compound 
heterozygote 
c.1123-1124 ins (TT) 
p.V375L 
fs*386 





















c. 1105-1126 del 





c.1122-1124 del (TGT) 
p.F374L 
p.375 del (V) 
compound 
heterozygote 






c.-35-1126 del  
compound 





c.1119-1124 del (CTTTGT) 
p.H373Q 
p.374-375 del (FV) compound 
heterozygote c. 1105-1126 del 
c.1130 del (T) 
p.K369R 
fs*428 
#23 c.1092-1121 del 
p.K364N 









#26 WT WT WT 


























heterozygote c.1104-1147 del  
+ 2 del (int 10-11) 
p.K369L 
fs*421 
#33 c.1092-1121 del 
p.K364N 





c. 1112-1117 del (CATACC) p.371-372 del (PY) 
 
Compound heterozygosity observed in some mES clones is attributable to different repair 
mechanisms occurring after DSBs. DSBs are predominantly repaired through homology-
directed repair (HDR) and non-homologous end joining (NHEJ) mechanisms. The activation 
of different repair mechanisms on two alleles and/or combined DNA repair on one allele can 
introduce many small (often single) deletions, insertions, and substitutions, which in turn lead 
to the generation of compound heterozygote clones carrying different mutations on each allele 





In a next step, I tried to introduce the Narf c.1118A>G mutation into the mouse genome. For 
this purpose, I designed and prepared a special homologous recombination DNA (HRD) 
template, which was co-transfected with the CRISPR Narf#3 plasmid and served as a 
template for HDR. The HRD template encompassed the position of the desired mutation (Narf 
c.1118A>G) and 100 nucleotides flanking homologous arms. To protect the HRD template 
from Cas9 cutting, I introduced an additional silent mutation (Narf c.1116C>T) in a CRISPR 
Narf#3-specific PAM sequence. I co-transfected EDJ #22 mouse mES cells with CRISPR 
Narf #3 and the HRD template (Figure 19a, left path). After 24 hours, I collected RFP-
positive cells through FACS. I then cultured them further to generate  mES cell colonies and, 
finally, mES cell lines. In total, I was able to establish 284 mES cell lines. I genotyped each 
line via PCR and subsequent Sanger sequencing. Out of these 284 mES lines, I obtained 6 
mES cell lines with a compound heterozygous (c.1118 A>G plus additional mutations as a 
result of combined HDR and NHEJ repair mechanisms) and 6 mES cell lines with a 
homozygous knock-in (KI hom; Figure 19a). Subsequently three KI hom clones were injected 
into blastocysts at Max Planck Institute of Experimental Medicine, Göttingen; this resulted in 
19 chimeric pups. Most of them were low-grade chimeras, with chimerism varying between 
5% and 25%, and only one male exhibited 60% chimerism (Figure 19b). Subsequently, I bred 
10 chimeric animals (including the male mouse with 60% chimerism) with wild-type animals 
and genotyped the offspring to monitor transmission of the mutant allele. I tested two to three 
litters from each breading pair, but all the offspring (F1 = 217) were wild type. To test 
whether KI mice embryos were dying during embryogenesis, I performed Sanger sequencing 
on DNA extracted from 18 embryos from two litters. None of them carried the introduced 
mutation. I carried out the same procedure on different tissues of chimeric males. Although I 
detected the introduced mutation in different tissues, I never detected it in testicular cells. This 
suggested that p.His373Arg homozygous ES cells do not contribute efficiently to the 
formation of chimeric mice and that they lack the viability to form germ cells. To overcome 
this problem, I opted to generate a heterozygous mES cell line and used this for blastocyst 
injection. To increase the likelihood of generating heterozygous mES cell lines, I slightly 
modified the experimental procedure. Briefly, I used two HRD templates: the one described 
above (c.1116C>T, c.1118A>G; HRD) and a second one, containing only a modified PAM 
sequence (c.1116C>T; HRD1). Again, I co-transfected mES cell line EDJ #22 with CRISPR 
Narf #3 and with both HRD templates (Figure 19a, right path) present in equal amounts 
during transfection. As described above, I selected cells via FACS, cultured RFP-positive 




positive mES cell lines I obtained, 3 were homozygous, and 10 were compound heterozygous, 
but none were heterozygous clones. I repeated this experiment and co-transfected with a 
higher concentration of HRDs, which resulted in 276 RFP-positive colonies, including 4 
homozygous, 6 compound heterozygous, and 3 heterozygous clones. three heterozygous 
knock-in mES (KI het ) were injected into blastocysts, resulting in seven low-grade chimeras. 
Due to these chimeras’ very low level of mosaicism and the resultant high likelihood of failed 
germline transmission of the mutation, I decided against subjecting them to further study. 





Figure 19: Generation of a p.H373R knock-in mouse model. (a) Schematic representation of strategy adopted 
for the generation of homozygous and heterozygous NARF
p.H367R
-KI mouse embryonic stem cells using 
CRISPR/Cas9 technology. After performing transfection with plasmid-encoding guided RNA, caspase 9 (Cas9), 
and a homologous recombinant DNA template, I obtained homozygous mES cells. The HRD contained a 
missense mutation corresponding to the mutation identified in the patient (c.1118A>G, green arrow) as well as a 
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additional HRD1. The HRD1 contained only a silent mutation in the PAM sequence. The chromatograms 
represent the results of Sanger sequencing of WT ES (upper) or KI mES cell lines, which I further used for 
blastocyst injection (lower). (b) Representative images of the 60% chimeric male obtained after the injection of 
homozygous Narf
p.H373R
 mES cells. 
 
Due to the inability to carry out further tests in vivo, I characterised the Narf function and the 
mutational effect using the generated mES cell lines. I used one KI hom and one KI het mES 
line (further referred to as Narf KI hom mES cells and Narf KI het mES cells, respectively). 
EDJ #22 WT cells (further referred to as Narf WT mES cells) served as a control. 
During culturing, I noticed differences between different clones in terms of the rate of cell 
proliferation. To analyse cell proliferation in detail, I performed a proliferation assay and 
measured changes in the number of cells within 48 hours after seeding the same number of 
cells. I then estimated the relative proliferation rates of the two tested cell lines and the 
control. The proliferation test indicated that Narf KI mES cells (both homozygous and 
heterozygous) proliferate significantly slower than Narf WT mES cells (Figure 20). This 
result suggested that the c.1118A>G mutation, whether in heterozygous or homozygous cells, 
impairs Narf function and engenders decreased proliferation. 
 
Figure 20: Proliferation assay in Narf KI mES cells. The cells reduce MTS tetrazolium into coloured 
formazan product which quantity can be measured. The quantity of formazan product reflecting the number of 
living cells was estimated by measuring of the absorbance at 490 nm with NanoDrop™ OneC 
Spectrophotometer. The KI mES cell lines (KI het and KI hom) proliferated significantly more slowly than the 
WT mES cells. The values and associated error bars represent the mean ± SD (n=3). The statistically significant 




























5.8 Genomic instability in Narf KI mES cells 
Because genomic instability is one of the main and well-described hallmarks of ageing 
(Lopez-Otin et al., 2013) and exerts an influence on cell proliferation, I was highly interested 
in determining whether this mechanism could explain the phenotype identified in KI mES 
cells. For this purpose, I treated Narf WT, KI het, and KI hom mES cells with etoposide (Eto) 
or UV-C radiation (UV) in order to induce DNA damage, and I measured the efficiency of 
DNA repair mechanisms in these cells. Etoposide is known to introduce DSBs in the DNA, 
which can be repaired by NHEJ or HDR, while UV light exposure results in the generation of 
single nucleotide lesions that are mainly repaired by the nucleotide exchange repair (NER) 
mechanism. An impaired or inefficient NER mechanism can in turn lead to the generation of 
DSBs (Rastogi et al., 2010). Thus, I treated the cells with either etoposide or UV-C light and 
monitored the phosphorylation of histone H2AX (γH2AX), a well-established marker for the 
presence of DNA damage. Subsequently, I collected the cells at three different time points (1, 
6, and 24 hours after the treatment/exposure) and submitted them for total protein extraction. 
Untreated cells served as the control in this experiment. Next, using WB analyses, I 
investigated the amount of γH2AX and total H2AX in the protein extracts. Etoposide 
treatment caused a dramatic increase in γH2AX levels within the first hour in all the different 
cell lines; the γH2AX levels then begin to slowly decrease over time (Figure 21a, upper 
panels). The relative values of the γH2AX amounts, estimated based on total H2AX 
expression, revealed no significant differences between cell lines in terms of the amounts of 
γH2AX (Figure 21b). UV radiation induces a gradual increase in γH2AX levels, which 
generally peak within six hours after exposure and then start to decline (Figure 21a, lower 
panels). The relative values of the γH2AX amounts, estimated as described above, indicated 
that the Narf KI hom mES cells exhibited higher γH2AX levels than the WT controls for a 
prolonged period; this suggested an impaired NER mechanism in this cell line (Figure 21c). 
The Narf KI het mES cells also presented elevated γH2AX levels 24 hours after treatment, 





Figure 21: Genomic instability in Narf KI mES cell lines. (a) Representative immunoblot illustrating the 
expression of phosphorylated (γH2AX) and total H2AX protein in WT and KI (heterozygous and homozygous) 
mES cells 1, 6, and 24 hours after treatment with etoposide (Eto, upper panel) or UV-C (lower panel). (b) Using 
the ImageLab software, I quantified the γH2AX band intensities after etoposide treatment and normalised them 
to their respective total H2AX band intensities, which are represented as relative values in a bar graph. After 
etoposide treatment, γH2AX levels dramatically increased within 1 hour and began to decline over time (6 h, 24 
Narf WT Narf KI het 








































































h). There were no significant differences between cell lines in terms of the amounts of γH2AX observed (two-
tailed t-test, p>0,05). (c) I quantified the γH2AX band intensities after UV-C exposure as described above. The 
UV-C irradiated cells exhibited a gradual increase in γH2AX levels within the first six hours after treatment; the 
γH2AX levels then began to decline. It was only in the Narf KI homozygous cells (KI hom) that I observed 
significant high levels of γH2AX in comparison to the WT cells (two-tailed t-test, *p<0.05). The values and 
associated error bars represent the mean ± SD (n=2). M = Precision Plus Protein™ All Blue Pre-Stained Protein 
Standards. 
 
In addition, I investigated whether knock-down of NARF influences genome stability in 
human fibroblasts. I generated human fibroblasts with knocked-down NARF gene through 
small interfering RNA (siRNA) (further referred to as NARF KD FB). I used the NARF KD 
FBs to the genomic stability analyses described above. The results demonstrated that 
fibroblasts in general are able to recover from DNA damage faster and more efficiently than 
ES cells: γH2AX appeared within 1 hour after etoposide treatment (Figure 22a, upper panels), 
and the UV light exposure led to a slow increase in the amount of γH2AX, which peaked 6 
hours after treatment and was then poorly detectable after 24 hours (Figure 22a, lower 
panels). Evaluation of γH2AX band intensities revealed no differences between the NARF KD 





Figure 22: Genomic instability in NARF knocked-down fibroblasts. (a) WB results depicting the amount of 
γH2AX and total H2AX protein in NARF KD and control fibroblasts 1, 6, and 24 hours after treatment with 
etoposide (Eto) or exposure to UV-C radiation (UV). (b) qRT-PCR results demonstrating the efficiency of 
siRNA knock-down (KD) of NARF in fibroblasts at the time of experiment. siRNA transfection reduced the 
expression of NARF to ~20%. The values and associated error bars represent mean ± SD (n=3). (c) Using the 
ImageLab software, I quantified the γH2AX band intensities after Eto or UV treatment and normalised them to 
their respective total H2AX band intensities, which are represented as relative values in a bar graph. There were 
no significant differences between the NARF KD and control cells (two-tailed t-test, p>0.05). The values and 
associated error bars represent mean ± SD (n=2). 












































5.9 Oxidative stress response in NARF in vitro models 
Since NARF homologues Nar1 and oxy-4 have been associated with oxidative stress in yeast 
and nematode, respectively (Fujii et al., 2009), I decided to investigate oxidative stress in 
NARF-compromised cells (mES cells and human fibroblasts). Therefore, I performed an 
oxidative stress response test using the commercially available CellROX™ Deep Red Flow 
Cytometry Assay Kit. Briefly, I induced the production of ROS in the cells, using tert-butyl 
hydroperoxide (TBHP). Next, I monitored the cellular response to this oxidative stress by 
staining the cells with CellROX® Deep Red reagent, which, as a reliable marker of ROS 
production in living cells, exhibits a strong fluorescent signal when oxidised. Simultaneously, 
I stained the cells with SYTOX® Blue Dead Cell to distinguish dead cells. I then measured 
and counted the fluorescent signals from both dyes by performing flow cytometry according 





Figure 23: Oxidative stress assay in Narf KI mES cells and NARF KD fibroblasts. (a) Flow cytometry 
analysis of untreated and TBHP-treated WT cells, KI mES cells, WT fibroblasts, and NARF KD fibroblasts. 
CellROX® Deep Red (APC-A) positive cells represent ROS-positive cells, while SYTOX® Blue (Pacific Blue-
A) positive cells represent apoptotic cells. (b) Evaluation of the flow cytometry results of the WT and KI mES 
cells. (c) Evaluation of the flow cytometry results of the WT and NARF KD fibroblasts. The untreated cells (both 
mES cells and fibroblasts) did not present any ROS-positive cells. Upon TBHP treatment, the ROS were 
activated, but there were no significant differences between treated cells and controls in terms of ROS generation 
or apoptosis (two-tailed t-test, p > 0.05). The values and associated error bars represent mean ± SD (n=2). (d) 
qRT-PCR results demonstrating the efficiency of siRNA knock-down (KD) of NARF in fibroblasts at the time of 
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experiment. siRNA transfection reduced the expression of NARF to ~30%. The values and associated error bars 
represent mean ± SD (n=3). 
 
Without stimulation, none of the examined cell lines exhibited ROS accumulation (Figure 
23a, untreated, Q4 squares). ES cells proved more sensitive to the staining procedures, as 
evinced in the higher number of apoptotic cells in the untreated cells than in the untreated 
fibroblasts, but no differences were observed between the Narf WT and KI mES cell lines or 
between the untreated and TBHP-treated cells (Figure 23a, Q1 squares). The TBHP treatment 
activated ROS production in all the cell lines in an equal manner, as compared to the WT 
controls (Figure 23a, TBHP treatment, Q4 squares). Induction of ROS production did not in 
itself lead to increased apoptosis, as double positive cells were barely detectable in all tested 
cell lines (Figure 23a, TBHP treatment, Q2 squares). When evaluating the flow cytometry 
results, I observed no significant differences between Narf KI mES cells and Narf WT mES 
cells or between NARF KD fibroblasts and control fibroblasts (Figure 23b, c, respectively) in 
terms of ROS accumulation (red positive cells) or apoptosis upon induction of oxidative stress 
(red/blue double positive cells). Using this assay, I was not able to demonstrate any impact of 
NARF on ROS accumulation or oxidative stress. Since the oxidative stress analysis was done 
at the end of my PhD-work, there was no time to perform additional and systematic analysis 






The main results obtained during my PhD project indicate that the cellular functions of NARF 
strongly depend on the proper localisation of protein within the nucleus. The mutation 
identified in patient prevents the nuclear translocation and causes cytoplasmic accumulation 
of protein. Functional analyses of protein interactions revealed novel insights into NARF’s 
interaction partners. I confirmed interaction between NARF and lamin A and additionally 
determined two novel interactions – with CBX5 and NARF itself. Demonstrating the ability 
of NARF to form homodimers was a key step to discovering the dominant negative effect of 
the identified mutation. Interestingly, I was able to show that mutation does not disrupt NARF 
interactions; nevertheless, it impairs the nuclear import of the created dimers. Functional 
testing of Narf-mutant cells exhibited malfunction of some cellular properties which are also 
connected with the ageing-pathways. The mutation causes impaired cell proliferation abilities 
and dysfunction of DNA repair mechanisms leading to genomic instability. These two 
diminished cellular activities may be the main reason of the failure in Narf KI mouse line 
generation. At the same time, I was not able to determine functional similarities between 
NARF and its homologues. In addition, I could have not confirmed/excluded participation of 
NARF in the regulation of the oxidative stress mechanisms – a common function for all 
NARF homologues among different species.  
6.1 Evolutionarily conserved function of NARF and its homologues 
NARF is 31% identical and 41% similar to yeast Nar1. Due to this structural homology, it has 
been suggested that NARF performs a function similar to that of Nar1. A complementation 
assay performed in the study of Balk et al. (2004) was unable to prove this hypothesis (Balk et 
al., 2004). The authors tested both NARFL and NARF, but found that neither of them appears 
to have an evolutionarily conserved function. Since the authors were unable to present the 
expression and functionality of the NARF/NARFL proteins used in their complementation 
assay, I repeated this experiment. In my study, I was able to overexpress the human 
homologues in Nar1-depleted yeast, but they failed to rescue yeast growth. Systematic studies 
on yeast-human orthologous gene pairs have revealed that sequence similarity can be helpful 
in predicting functional rescue: sequence similarity is higher for complementing pairs (45%) 
than non-complementing pairs (29%) (Sun et al., 2016). At the same time, it has also been 
shown that the human non-orthologous protein may act as a functional substitute for the yeast 




predicted by sequence similarity (Hamza et al., 2015; Kachroo et al., 2015). Failure in the 
complementation assay could also be attributable to incorrect conformation of tagged human 
proteins, which in turn could cause the expression of non-functional proteins in yeast cells. As 
was demonstrated in this study, both the NARF and the NARFL proteins tagged with BFP2 
exhibited untypical aggregation in the cytoplasm. Tagging of proteins with fluorescent 
epitopes can be helpful in determining the expression and proper localisation of the 
introduced protein; however, it can also lead to a decreased expression level and/or toxicity of 
the heterologous protein (Tugendreich et al., 2001). It is also known that complementation 
efficiency strongly depends on the cellular function of proteins. Systematic analyses indicate 
that a function-specific group of proteins can be almost completely replaceable (e.g. 
metabolic enzymes, which have over 90% replaceability), poorly replaceable (e.g. DNA 
replication and repair genes, which have 35% replaceability), or not replaceable at all (e.g. 
cell growth and dead genes, which have only 3% replaceability) (Kachroo et al., 2015), 
suggesting species-specific pathways that cannot be reproduced in different organisms. 
Considering that NARF contributes also to the maintenance of genomic stability and DNA 
repair, it falls into a group of proteins that is difficult to replace. Another species-specific 
feature that can prevent complementation is the protein-protein interactions network. This was 
illustrated in the example of human and yeast proteins involved in meiotic recombination, 
mitotic DNA repair, and telomere maintenance. The human MRE11B gene, which is a 
homologue of the yeast MRE11 gene, was not able to rescue mre11 mutants due to the lack of 
necessary interactions with yeast proteins (Chamankhah et al., 1998). Homologous proteins 
can contain conserved domains ensuring their conserved function among different organisms, 
but they can differ in terms of the remaining structure of the protein, and this part of the 
protein is species-specific. Such a situation has been described in proteins engaged in splicing 
and cell cycle control: Prp16 and Prp17, containing conserved WD repeats motifs in the C-
terminal of proteins. The human PRP16 and PRP17 genes have both failed to exhibit the 
ability to rescue yeast prp16 and prp17 mutants, respectively. The generation of chimeric 
proteins composed of yeast N-terminal and human conserved C-terminal parts, however, has 
been found to result in functional replacement in both cases, indicating a species-specific role 
of the N-terminal part of yeast proteins (Ben Yehuda et al., 1998; Zhou and Reed, 1998). In 
the case of the examined Nar1, NARF, and NARFL homologues, all three share conserved C-
terminal cysteine residues coordinating the H-cluster characteristic for iron-only hydrogenases 
(Balk et al., 2004). The generation of chimeric proteins containing the C-terminal H-cluster of 




culminating in improved functional complementation in yeast. Moreover, it has been 
proposed that selecting an adequate promoter for protein expression can be important in 
complementation assays. The commonly used constitutive or inducible promoters lead to 
artificial overexpression of the tested proteins; this, in turn, can disrupt the balance required 
for the proper protein function, thus leading to a lack of complementation (Lo Presti et al., 
2009). In my study, all proteins used in the complementation assay were expressed from the 
inducible Met25 promoter. To rule out the possibility that suboptimal concentrations of 
NARF and NARFL block complementation of the Nar1 function in yeast, it may be advisable 
to try using native promoters. In general, there is no available set of common conditions that 
can ensure successful complementation, because each human-yeast gene pair is unique 
(Hamza et al., 2015). NARFL and Nar1 seem to be more closely related, as both are important 
players in the cytosolic iron-sulphur cluster assembly (CIA) machinery in mammals and 
yeast, respectively, but NARFL is still unable to substitute for the Nar1 function. The lower 
organisms, such as yeast or nematodes, possess only one homologue of this hydrogenase-like 
protein (Nar1 or oxy-4, respectively), whereas two (NARF and NARFL) are presented in 
higher eukaryotes, such as mammals. Many examples demonstrate that more complex 
organisms possess more than one homologue of essential genes. An excellent example is a 
group of genes involved in the NER mechanism, including the yeast RAD6 gene and its 
human homologues, HHR6A and HHR6B, and the yeast RAD23 gene and its human 
homologues, HHR23A and HHR23B (Koken et al., 1991; van der Spek et al., 1994). One can 
imagine that the NAR1 gene might have split its function into two homologues during 
evolution. In this way, emerging proteins with structural homology can fulfil different 
functions. This would explain why neither NARF nor NARFL can replace the Nar1 function 
separately, raising the question of whether the two together would be able to replace the Nar1 
function. Another interesting experiment would be to perform the complementation assay the 
other way around, using human and/or mouse cell lines lacking expression of the NARF/Narf 
and NARFL/Narfl genes to test the potential of the yeast NAR1 or the nematode OXY-4 gene 
to rescue the phenotype. Such an assay would allow for testing the ability of invertebrate 
proteins to complement mammalian proteins’ functions. On the example of centromere 
proteins, it has been demonstrated that functional complementation can be examined in both 
ways because the yeast Cse4p homologue can substitute for a lack of the human CENP-A 




6.2 Failing in the generation of specific NARF antibodies 
There are two ways to immunise animals for antibody production: host animals can be 
injected either with the full-length protein or with short synthetic peptides (usually 1020 
amino acids in length; (Lee et al., 2016a). Both methods present advantages and 
disadvantages. Immunisation with the full-length protein allows for generating antibodies 
against multiple epitopes along the sequence. This in turn increases the chance that the 
generated antibodies will be able to detect at least one of these epitopes in native protein. At 
the same time, specificity to numerous epitopes can induce unspecific binding to other 
proteins possessing homologous sequences (pacificimmunology.com). The second strategy, 
immunisation with short peptides, ensures higher specificity of the produced antibodies (Trier 
et al., 2012), but in some cases, the target epitope is internally located in native protein, 
preventing the recognition and binding of the antibody (Lipman et al., 2005; Trier et al., 
2012). In my approach, I tried to generate common antibodies against mouse and human 
NARF. For this purpose, I used two 16-amino-acid peptides that are complementary to both 
the mouse and the human protein. The generated antibodies passed all the internal quality 
controls; however, the specificity of the generated antibodies was tested on peptides used for 
immunisation but not on cell/tissue protein extracts. Since an antibody’s specificity can be 
defined as its ability to recognise a particular epitope in the presence of other epitopes (Trier 
et al., 2012), the first specificity control was the WB analyses conducted in our lab. As 
illustrated in the results section, the antibodies were unable to recognise the endogenous 
NARF protein, instead displaying higher affinity to β-actin. In parallel, the generated 
antibodies recognised exogenous NARF protein artificially overexpressed in cells. The reason 
why they were unable to bind to the endogenous protein could relate to low quantity of 
endogenous NARF or the conformation of its native form, which may have precluded the 
antibodies from finding the specific epitope used for immunisation. The use of another 
peptide or the full-length protein for immunisation could perhaps enable successful antibody 
production. The 3D structure of the NARF protein would be helpful in selecting the optimal 
protein sequence for immunisation; otherwise, it has often been shown that exposed regions, 
such as N- or C-terminal parts, can constitute effective targets (Trier et al., 2012). Ultimately, 
it might be worth endeavouring to generate monoclonal antibodies (mAb), which provide 




6.3 New insights into NARF interactions  
To validate a previously described interaction between NARF and pre-lamin A (Barton and 
Worman, 1999) and to identify novel interaction partners of the NARF protein, I also 
conducted a Y2H experiment. In contrast to the previous report, the Y2H experiment 
conducted within this study failed to substantiate a NARF-pre-lamin A interaction. The main 
difference between my study and the study conducted by Barton and Worman (1999) is based 
on the direction of screening. Whereas Barton and Worman used lamin A as the bait, NARF 
served as the bait in my study. The other possible explanation for the disparity is that the two 
studies used different cDNA libraries. Barton and Worman (1999) used a cDNA library from 
HeLa cells (Barton and Worman, 1999), while I performed my screening on human ventricle 
and embryo heart cDNA libraries. I decided to use heart libraries because patient harbouring 
the NARF
p.H367R
 mutation tend to display early onset of dilated cardiomyopathy. According to 
the Human Protein Atlas (proteinatlas.org), both NARF and lamin A are expressed in HeLa 
cells and heart muscle; however, it would be difficult to exclude the possibility that switching 
the assay direction or the library used in a Y2H assay can change the concentration and 
balance of the tested interaction partners, thereby influencing the interaction. The possibility 
that different outcomes originating in experiments conducted to search for interaction 
partners, especially Y2H assays, result from using different baits and libraries has already 
been published. Using a C-terminus of lamin A as the bait to screen a human skeletal muscle 
cDNA library identified COMMD1 as a novel binding partner of lamin A (Jiang et al., 2019), 
while screening the same cDNA library with full-length pre-lamin A as the bait allowed for 
identifying FAM96B as a lamin A interaction partner (Xiong et al., 2013). Using mouse lamin 
A has also resulted in identifying various interactions: a Y2H assay employing the C-terminus 
of mouse lamin A and the mouse 3T3-L1 adipocyte cDNA library uncovered interactions 
between lamin A and the Srebp1 and Srebp2 proteins (Lloyd et al., 2002). Interestingly, 
another group identified another lamin A binding partner, Sun1, using the same screening bait 
and library (Haque et al., 2006). These different interactions in different tissues may explain 
why mutations in one gene can inflict numerous forms of various disorders (Rankin and 
Ellard, 2006; Worman and Bonne, 2007), but they also hinder the identification of novel 
interaction partners. They may also explain why even more comprehensive studies adopting 
different systems have failed to identify NARF as an interaction partner of pre-lamin A/lamin 
A (Dittmer et al., 2014; Kubben et al., 2010). Nevertheless, I was able to validate a direct 




independent tests because the CoIP assay yielded unreproducible results. The technical 
difficulties associated with an IP experiment involving lamin A stem from its biochemical 
properties, which impede both the solubility of lamin A and the extraction of an intact protein 
complex. Conversely, stricter solubility conditions enable lamin A extraction, but disrupt 
interactions (Kubben et al., 2010). 
The Y2H assay pointed to two novel interaction partners of NARF, one of which is CBX5. 
CBX5 (heterochromatin protein 1α – HP1α) is one of three non-histone chromatin-associated 
proteins belonging to the HP1 family (Lomberk et al., 2006). It controls heterochromatin 
organisation and gene silencing by binding to tri-methylated lysine 9 on histone H3 
(H3K9me3) through the N-terminal chromo domain (CD) (Bannister et al., 2001; Lachner et 
al., 2001). Like lamin A, CBX5 has been shown to be involved in the accelerated ageing 
phenotype. Furthermore, it delayed DNA damage repair in Zmpste24-deficient mouse 
embryonic fibroblasts (MEFs) obtained from knock-out mice (Liu et al., 2014). Such findings 
render CBX5 an interesting partner for further investigation. In line with my study, more 
extensive proteomic analyses of HP1-binding proteins (HPBPs) revealed that CBX5 interacts 
with NARF (Nozawa et al., 2010). I confirmed this interaction in vitro, using two methods: a 
BiFC assay and a pull-down assay using recombinant CBX5 protein expressed in bacteria. I 
chose to use a pull-down assay to study this interaction due to similar difficulties with respect 
to the extraction of an intact NARF-CBX5 complex in CoIP experiments. Moreover, the pull-
down assay revealed that the interaction between NARF and CBX5 is not disrupted by the 
p.H367R mutation in NARF, as I was able to demonstrate that mutant NARF also interacts 
with recombinant CBX5 in vitro. Using BiFC experiments, I attempted to examine the 
localisation of complexes of NARF
p.H367R
 and both lamin A and CBX5; however, the results 
were inconclusive, revealing interacting proteins expressed in the nucleus and/or cytoplasm 
(data not shown). To overcome such ambiguous observations, it would be interesting to 
examine the localisation of these protein complexes over time because in all the BiFC assays, 
I fixed the cells and scrutinised them under the microscope at only one time point: 24 hours 
after transfection. A temporal analysis would offer insight into whether this dual localisation 
is attributable to dynamic processes of transfer of protein complexes or merely stems from the 
artificial situation created in vitro. 
Most interestingly, the Y2H assay also uncovered a third possible interaction of NARF, which 
has not been previously described: a NARF-NARF interaction, which suggests the creation of 




assay as well. Furthermore, the co-localisation of proteins in nuclear compartments indirectly 
corroborated all three of the discovered interactions. I found that NARF co-localises with 
lamin A within the nuclear envelope, but it is also expressed with CBX5 in the nucleoplasm.  
6.4 Mislocalisation of NARF mutant protein and dominant negative effect 
Unlike its cytoplasmic homologues, NARF has been described as a nuclear protein (Barton 
and Worman, 1999). In line with the result of a study conducted by Barton and Worman 
(1999), I identified overexpressed NARF in the nuclei of HeLa cells. Subsequently, I 
demonstrated that the patient-specific mutation causes mislocalisation of the NARF
p.H367R
 
protein presented exclusively in the cytoplasm. It was clearly established that mutations of the 
conserved histidine disturb the nuclear transport of the protein. Several pathways enable the 
nuclear import of proteins through nuclear pore complexes (NPCs): (1) canonical nuclear 
import mediated by importins α/β; (2) passive diffusion of small proteins; (3) travelling in a 
“piggyback” manner, using other interaction partners as transporters; (4) direct interaction 
with nucleoporins in the NPCs; (5) using the cytoskeleton to efficiently accumulate at the 
nuclear periphery, from where proteins can be easily carried by transporters; (6) using 
calmodulin/calreticulin as other transporting proteins in a calcium-dependent manner; (7) 
glycol-dependent transport via the leptin family of proteins (Bauer et al., 2015; Wagstaff and 
Jans, 2009). Active nuclear import requires the presence of nuclear localisation signal (NLS) 
in cargo proteins; NLS is recognised by importin α. Importin α subsequently interacts with 
importin β, acting as a linker between cargo proteins containing NLS and importin β, which 
ensures final transport via direct interactions with nucleoporins in the NPCs (Bauer et al., 
2015; Christophe et al., 2000; Schlenstedt, 1996; Wagstaff and Jans, 2009). Since no classical 
NLS (cNLS) has been identified within the NARF sequence (as evaluated by cNLS Mapper, 
nls-mapper.iab.keio.ac.jp), it is important to consider other possibilities for the nuclear 
transport of NARF. Findings from the Y2H experiments indicated that NARF forms a 
homodimer. This insight might prove conducive to penetrating the process of the nuclear 
transfer of NARF, since I demonstrated that the p.H367R mutation exerts a dominant negative 
effect on the WT protein. Proteins very rarely operate as a single unit (Marianayagam et al., 
2004; Matthews, 2012), and protein-protein interactions are instrumental in inducing most 
biological processes (Klemm et al., 1998). One of these widespread protein-protein 
interactions is dimerisation, which can be defined as an interaction between related subunits 
(Klemm et al., 1998). Dimerisation of proteins enhances the stability of proteins, increases the 




binding sites in proteins engaged in DNA replication, DNA repair, and gene expression 
(Marianayagam et al., 2004; Mei et al., 2005). In addition, the formation of dimers requires 
less energy than long monomer synthesis and can assist in avoiding random associations (Mei 
et al., 2005). The generation of more complex structures also provides extended interaction 
surfaces, thus enabling simultaneous binding to other proteins and the formation of larger, 
better functioning complexes (Klemm et al., 1998; Marianayagam et al., 2004). Moreover, it 
has been revealed that the dimerisation of different types of proteins plays numerous roles in 
almost all signal transduction pathways (Klemm et al., 1998). The data collected here indicate 
that NARF performs its function in the nucleus most likely as a homodimer. Formation of this 
homodimer can also regulate its nuclear import or, at least, the generation of an 
unconventional ‘structural’ NLS. A similar situation has been described for the signal 
transducer and activator of transcription (STAT1). STAT1 nuclear localisation is ensured 
through tyrosine phosphorylation, followed by dimerisation. This dimerisation allows for 
generating an unconventional NLS that is subsequently recognised by importin-α5, resulting 
in nuclear import of the STAT1 dimer. Furthermore, it has been shown that the p.L497A 
mutation in STAT1 impairs the interaction of the STAT1 dimer with importin-α5 (and, in 
turn, impairs nuclear localisation), but does not impair phosphorylation, dimerisation, or DNA 
binding (McBride et al., 2002). These outcomes indicate that the NLS of the STAT1 protein 
becomes functional upon conformational changes that occur as a result of dimerisation 
(McBride et al., 2002). The functional heterogeneity of the importin α protein family and the 
capacity of its members to interact with multiple proteins via distinct domains (Miyamoto et 
al., 2016) support the possibility that dimerisation of the NARF protein also might generate a 
structural NLS that can be recognised by one of the family members. Conducting direct 
NARF interaction studies incorporating individual members of both the importin alpha and 
importin beta protein families could be helpful in determining whether these proteins are 
directly involved in the nuclear transport of NARF. Nevertheless, the possible presence of 
non-classical NLS within the NARF monomer cannot be completely excluded. The presence 
of unconventional NLS is reported frequently, on a case by case basis, and has been 
demonstrated in studies on particular nuclear proteins. Cloning approaches have also revealed 
some sequences that do not demonstrate specific characteristics but are partially similar to the 
sequences of known nuclear proteins, indicating that the pool of functional NLSs may be 
much larger than expected (Christophe et al., 2000). It would be worthwhile to explore the 
possibility of identifying new non-classical NLS within the NARF sequence. This could be 




sequences that may function as NLS and fusing these sequences with a reporter protein, such 
as a fluorescent protein. Subsequently, the resultant fused fragments could be expressed in 
cells, and their ability to localise in nuclei could be evaluated under a microscope, especially 
for fragments including the highly important histidine at position 367. Such a process might 
reveal whether NLS-like sequences exist in the NARF protein. At the same time, NARF can 
also ‘travel’ to the nucleus in a ‘piggyback’ manner, using its interaction partners as 
transporters, since both lamin A and CBX5 possess cNLS sequences.  
I demonstrated that mutations in NARF do not disrupt its interactions, or, at least, they do not 
disrupt its interaction with CBX5 in vitro. Unclear results regarding the localisation of mutant 
protein interactions, however, do not allow for evaluating whether mutations also change the 
location of NARF
p.H367R
-partner complexes. As mentioned previously, repeating this 
experiment in a more precise, time-dependent manner could offer insight into this issue. 
Direct interaction studies could also be conducted to shed light on two other pathways of 
nuclear transport: interactions with NPCs and the cytoskeleton. The possibility that NARF is 
able to interact with nucleoporins, which build NPCs, and enters the nucleus via direct 
binding with nucleoporins should be explored. It is also worth examining whether NARF can 
use microtubular/actin filament movement to facilitate conventional nuclear import through 
accumulation at the nuclear periphery. Since there is no evidence for post-translational 
glycosylation of the NARF protein or its calcium-dependent function, it is unlikely that it can 
travel via calmodulin or leptin proteins. NARF is also too large to passively diffuse through 
the nuclear envelope. Evaluation of all the reviewed mechanisms of nuclear import can help 
to establish the particular pathway(s) that are used by NARF. It has been revealed that many 
proteins with critical nuclear roles have evolved the ability to use numerous mechanisms of 
nuclear transport that enable them to localise efficiently in the nucleus under different 
conditions, especially in situations where conventional nuclear import fails (Wagstaff and 
Jans, 2009). It is important, however, to heed the crucial role of dimerisation and the essential 
contribution of the histidine at position 367. It has been demonstrated that, due to pH-
dependent changes in histidine chemistry (Li and Hong, 2011), histidine residues can play a 
critical role in protein dimerisation (Medina et al., 2019) and ligand binding/releasing 
(Rotzschke et al., 2002). Crystallographic examination of the three-dimensional (3D) 
structures of NARF dimers would be an excellent tool to identify conformational changes 
induced by histidine substitution. In addition to mislocalisation of the NARF
p.H367R
 protein, it 




accelerated degradation compared to WT NARF. Increased degradation of mislocalised 
proteins has been described for the transmembrane proteins that accumulate in the cytoplasm 
and cannot undergo proper folding (Hessa et al., 2011; Suzuki and Kawahara, 2016). The 
degradation of mislocalised NARF may suggest two possibilities: (1) nuclear localisation of 
the protein prevents its degradation, therefore mislocalised NARF is degraded in the 
cytoplasm, or (2) histidine substitution causes improper structure of the NARF dimer that not 
only disturbs nuclear transport but also becomes a signal for degradation. According to my 
results, however, decreased stability of NARF
p.H367R
 can be observed in single-transfected 
HeLa cells. It could be interesting to explore the possibility that interaction with the WT 
protein in double-transfected cells can rescue mutant degradation.    
6.5 Failing of Narfp.H373R mouse model generation 
Another aim of my research project was to generate a Narf
p.H373R
-KI mouse line as an in vivo 
model for functional study of Narf, a newly identified progeroid-associated gene. Gene 
editing by homologous recombination (HR) in mES cells has been a powerful tool to evaluate 
the function of a gene in vivo. The classical protocol for the generation of KI entails 
transfection of mES cells with a homologous recombination DNA template, which is used 
later for HR. The frequency of spontaneous recombination is extremely low and necessitates 
intense screening to identify positive clones. This renders the process extremely time-
consuming (Sato et al., 2016). To facilitate and expedite the process, I decided to use the 
CRISPR/Cas9 system, which, combined with HRD templates, provides precise and specific 
HR at a specifically determined region in the genome (Jinek et al., 2012). I used the EDJ #22 
mES cell line for mouse genome editing. As previously reported, this mES line contributes 
efficiently to chimera, leading to the generation of germline-transmitting male chimeras 
(Auerbach et al., 2000). The production of chimeras is a common intermediate step in the 
establishment of a mouse line, which additionally allows for following cell behaviour during 
both prenatal and postnatal development (Eakin and Hadjantonakis, 2006). To create a 
chimeric mouse, I employed one of the most common methods: injection of cells into the 
blastocoel cavity of a blastocyst stage embryo (Eakin and Hadjantonakis, 2006). This 
approach enabled to generate low-grade chimeras, which do not transmit KI alleles to 
offspring. Several key factors can affect the contribution of mES cells in the formation of 
germ cells, including the genetic background, the cell injection procedure itself, and 
chromosomal abnormalities and epigenetic alterations as a result of long-term culture and in 




both, the generated Narf KI cell lines, which were injected into the blastocysts, carried a 
homozygous silent mutation in the PAM sequence. This variant was not associated with any 
changes in protein sequence; however, we are not able to predict its overall impact on gene 
function. Another cell line, carrying only this mutation, should be generated in the next trial 
of mouse model generation as a negative control. This will allow for controlling whether this 
change exerts an impact on genes behaviour and contribution to germ cell formation itself. In 
my first attempt at mouse line generation, I embraced the use of a homozygous Narf KI mES 
line, which failed in germ cell formation. This raised the assumption that a homozygous 
mutation might be deleterious for mES cells and prevent their proper contribution to 
proliferation and differentiation during development. To overcome these complications, I 
additionally used heterozygous Narf KI mES cells in the second trial. Unfortunately, the 
observed results were similar, as this cell line was able to create only poor, low-grade 
chimeras. This result might be due to the previously mentioned dominant negative effect of 
the introduced mutation and impaired proliferation of Narf KI mES cells.  
Today the procedure of mouse model generation can be rendered easier and faster by 
eliminating particular steps required in conventional mES cell injection into blastocysts. 
Currently, instead of blastocysts, a two-cell stage zygote is used, and DNA modifications are 
introduced directly into the zygote through direct introduction of DNA, RNA, or 
ribonucleoproteins. The injection, in turn, has been replaced by other methods, such as 
microinjections, electroporation, viral transfection, or even direct delivery into male or female 
gonadal tissues (Gurumurthy and Lloyd, 2019; Sato et al., 2016). These advanced methods in 
genomic engineering have recently allowed for obtaining new efficient protocols for mouse 
gene editing, such as by CRISPR ribonucleoprotein (RNP) electroporation of zygotes 
(CRISPR-EZ) (Modzelewski et al., 2018). Moreover, it has been demonstrated that large gene 
cassettes can be introduced into the mouse genome using CRISPR RNP electroporation and 
adeno-associated virus (AAV) donor infection (CRISPR-READI) (Chen et al., 2019). This 
approach has been used to correct mouse hematopoietic stem and progenitor cells (mHSPCs) 
and restore B and T cell development in vivo (Tran et al., 2019). It would be worthwhile to 
consider using one of these new methods in future experiments to bypass the time-consuming 
and problematic nature of dealing with mES cells and chimeras. Nevertheless, the essential 
function of Narf might also be the reason that Narf-mutant mES cells do not contribute in the 




6.6 Molecular function of NARF 
6.6.1 Oxidative stress regulation as conserved function of hydrogenase-like proteins 
As regulators of the oxidative stress response, all the identified NARF homologues share a 
common function. NARFL cooperates with hypoxia-inducible factor (HIF-1α) and serves as a 
regulator to maintain stable levels of HIF-1α. Knock-down of NARFL increases the 
expression of HIF-1α and its target genes under hypoxia and normoxia conditions (Huang et 
al., 2007). Recently, it has been reported that a homozygous mutation found in human NARFL 
caused pulmonary arteriovenous malformations (PAVMs) in two patients (Liu et al., 2017). A 
zebrafish model with narfl deletion revealed abnormal angiogenesis upon increased oxidative 
stress and upregulation of HIF-1α (Luo et al., 2019). Our patient with the NARF mutation, 
however, exhibited no malformations in her vascular system. Overexpression of NARFL in 
hyperoxia-resistant HeLa sublines also suggests that it plays a role in protecting both cytosolic 
and nuclear Fe-S proteins in hyperoxic environments (Corbin et al., 2015). Furthermore, a 
mutation found in Caenorhabditis elegans homologue OXY-4 (Y54H5A.4), in the same region 
as the mutation found in our patient, has been shown to induce increased sensitivity to 
oxidative stress and decreased lifespan in worms (Fujii et al., 2009). Depletion of yeast Nar1 
also leads to increased sensitivity to oxygen and lethality of yeast under hypoxic conditions 
(Fujii et al., 2009). The plant NAR1 homologue has also been found to play an important role 
in the oxidative stress pathway in Arabidopsis thaliana; however, in this case, nar1 mutants 
exhibited resistance to oxidative stress induced by paraquat (Nakamura et al., 2013). At the 
same time, an impaired response to oxidative stress has been reported in the fibroblasts of 
patients with atypical progeroid syndrome (APS)/atypical Werner syndrome (AWS) with a 
mutation in LMNA (Motegi et al., 2016). Nevertheless, in my study, I found that Narf 
mutations in mES cells exerted no influence on ROS production or on sensitivity to increased 
ROS levels in cells. I also found that NARF KD in human fibroblasts exerted no influence on 
the same variables. A general role of NARF in regulating the response to changing levels of 
oxygen, however, cannot be completely excluded on the basis of these outcomes. As has been 
demonstrated for nematode, yeast, and human cells, cultures in different oxygen 
concentrations can point to an impact on oxygen sensitivity. Therefore, it would be 
worthwhile to examine mES Narf-KIs and NARF-KD fibroblasts in both increased and 
decreased levels of oxygen and establish their behaviour under different oxygen conditions. 
Moreover, the presence of up- and down-regulated antioxidant enzymes and lower antioxidant 




(Seco-Cervera et al., 2014). This downstream pathway of antioxidant defence against ROS 
accumulation should also be examined in in vitro models of Narf mutants. This can be 
accomplished by measuring the expression of antioxidant enzymes such as superoxide 
dismutase, catalase, thioredoxin, or glutaredoxin. It is important to evaluate the levels of these 
enzymes not only at the messenger RNA (mRNA) level but also at the protein level. It has 
been revealed, in an example of WRN cell lines from patients with Werner progeria 
syndrome, that gene expression and protein levels do not correlate completely and that 
posttranscriptional protein modification may also play an important role (Seco-Cervera et al., 
2014). 
6.6.2 Reduced cell proliferation capabilities  
Both the Narf KI het and hom lines exhibited impaired proliferation caused by the introduced 
mutation. Similar outcomes have been observed for both Narfl, knock-down of which 
decreased the viability of mouse embryonic fibroblasts (MEFs) (Song and Lee, 2011), and 
Nar1, depletion of which led to yeast growth arrest (Balk et al., 2004). Impaired proliferation 
of cells carrying Narf mutations can explain some of the congenital and ageing features that 
presented in our patient. It has been reported that impaired proliferation e. g. can result in 
short stature. For example, it has been demonstrated that defects in chondrocyte proliferation, 
which is necessary for maintaining growth plate architecture and function, can result in a 
dwarfism phenotype (Koparir et al., 2015; Terpstra et al., 2003). Short stature is also a 
common characteristic in patients with WS and HGPS. The proliferative ageing that occurs in 
WS cells is connected with telomere shortening, whereas the proliferative ageing that occurs 
in HGPS occurs from defects in nuclear lamin, independent of telomerase activity (Zucchero 
and Ahmed, 2006). In addition to localisation in the nuclear lamina, lamin A locates in the 
nucleoplasm, in a complex with lamina-associated polypeptide (LAP2α). Loss of this 
complex increases cell proliferation, but in the presence of the progerin in HGPS cells, low 
LAP2α levels result in impaired proliferation. These data indicate that, depending on the level 
of lamin A in the nuclear interior, LAP2α can either promote or inhibit proliferation (Vidak et 
al., 2018). In cells lacking nuclear NARF, levels of nuceloplasmic lamin A might be impaired, 
resulting in a similar effect and a defect in proliferation. This may suggest a role of NARF in 
the localisation of its interacting partner lamin A within nuclear compartments. Moreover, it 
has been reported that the proliferation capacity of cells can be strongly dependent on their 
oxygen sensitivity and DNA damage repair abilities. It has been shown that mouse embryonic 




accumulate more DNA damage in 20% oxygen. DNA damage in MEFs was also higher than 
DNA damage in human fibroblasts in 20% oxygen. This indicates that oxygen sensitivity can 
determine differences between mouse and human cell cultures and explain their proliferative 
differences in vitro (Parrinello et al., 2003). These data should be considered in future 
experiments involving mouse and human cells presenting NARF mutations. These findings 
point to the importance of distinguishing the role of NARF in oxidative stress response and 
cell proliferation or determining the overlap between these two pathways. Another of our 
patient’s features that can be explained by impaired cell proliferation is microcephaly. This is 
a developmental brain anomaly that is rooted in defective proliferation of neuroprogenitors; it 
presents, for example, in patients with a mutation in RTTN. RTTN participates in cellular 
proliferation and neuronal migration and is involved in both isolated primary microcephaly 
and microcephalic primordial dwarfism (Shamseldin et al., 2015). Proliferation defects 
causing microcephaly have also been described in patients harbouring mutations in proteins 
involved in mitotic regulation and progression (Cavallin et al., 2017; Gilmore and Walsh, 
2013; Sgourdou et al., 2017). 
6.6.3 Impaired DNA damage repair and genomic instability 
Genome stability is predominantly ensured by the proper functioning of the DNA damage 
repair mechanisms in cells. The cellular response to DNA damage is primarily based on 
initiation of the cascade of DNA damage response pathways (DDRs). DDRs are stimulated by 
lesion-specific sensor proteins that provide sufficient time for particular repair mechanisms to 
physically remove and exchange lesions. There are at least five major DNA repair 
pathways—base excision repair (BER), nucleotide excision repair, mismatch repair (MMR), 
homologous recombination (HR), and non-homologous end joining—which become activated 
at different cell cycle stages and respond to different types of damage (Chatterjee and Walker, 
2017). To explore the possibility that NARF can regulate this process, researchers have tested 
genome stability in mES cells with Narf mutants (Narf-KI het and Narf-KI hom) by inducing 
DNA damage using etoposide and UV treatment to create DSBs and pyrimidine 
photoproducts (PPs), respectively (Montecucco and Biamonti, 2007; Sinha and Hader, 2002). 
Their results have indicated that the Narf-KI homozygous mutation affects the DNA repair 
mechanisms of UV-induced lesions, but not etoposide-induced DSBs. It is known that UV 
light irradiation engenders the creation of PPs, which are mostly repaired by NER, and NER 
malfunction can in turn lead to the generation of DSBs (Rastogi et al., 2010). A closer look at 




xeroderma pigmentosum group D (XPD) or Fanconi anaemia complementation group J 
(FANCJ) are involved. XPD is a part of the 10-subunit complex transcription factor II human 
(TFIIH), which plays a role in both transcription initiation and in the NER pathway. FANCJ 
proteins are involved in the NER and Fanconi anaemia repair pathways, respectively (Rudolf 
et al., 2006). Dysfunction of these genes in humans causes xeroderma pigmentosum, 
Cockayne syndrome, trichothiodystrophy, or Fanconi anaemia (Lill, 2009; Lill and 
Muhlenhoff, 2008); some of these are described as progeroid syndromes. So far, the exact 
mechanism through which NARF regulates genome stability is unknown; however, both of its 
interaction partners, lamin A and CBX5, have been found to participate in DNA repair 
mechanisms. In the case of HGPS, defects in DNA repair pathways, telomere maintenance, 
epigenetic alterations, and oxidative stress all contribute to observed genomic instability 
(Gonzalo and Kreienkamp, 2015). Heterochromatin protein 1 (HP1) proteins regulate 
heterochromatin relaxation upon mobilisation via phosphorylation induced by DNA damage 
(Ayoub et al., 2008; Goodarzi et al., 2008; Ziv et al., 2006). In Zmpste24
-/-
 cells lacking the 
zinc metalloproteinase which takes part in post-translational cleavage and maturation of lamin 
A, the phosphorylation of threonine at position 50 (pT50) and, in turn, the DNA damage 
response has been found to be significantly delayed due to the accumulation of pre-lamin A 
and the disorganisation of heterochromatin (Liu et al., 2014). Stabilisation of CBX5 through 
inhibition of its proteasomal degradation in a lamin-A-dependent manner has been described 
(Chaturvedi et al., 2012; Chaturvedi and Parnaik, 2010). There are studies indicating that pre-
lamin A interacts with CBX5 and that the farnesylation of pre-lamin A decreases the capacity 
for this binding (Lattanzi et al., 2007), while NARF interacts with pre-lamin A in a 
farnesylated manner (Barton and Worman, 1999). Conversely, another study maintains that 
CBX5 is able to interact with pre-lamin A, lamin A, and lamin C (Liu et al., 2014), suggesting 
that binding sites for CBX5 and NARF are localised at different positions along the lamin A 
sequence. This raises a hypothesis that NARF could be a missing link between pre-lamin A 
and CBX5, thereby ensuring proper localisation inside the nucleus and binding of these 
proteins. In this case, mislocalisation of the NARF dimer prevents its functions in the nucleus.  
All the experiments conducted in the in vitro model composed of Narf-KI het/hom mES cells 
and NARF-KD FB cell lines demonstrated that the introduced point mutation in both the 
heterozygous and homozygous states exerted a greater impact on cellular functions 
(proliferation, UV light sensitivity) than decreased expression of the NARF gene. It is 




complete and the lack/diminished expression of the protein was not confirmed due to the 
failure to generate anti-NARF antibodies and the absence of proper protein expression 
control.  
6.7 Is NARF iron-sulphur protein? 
As outlined in the introduction part, NARF and its homologues are similar to bacterial iron-
only hydrogenases. Hydrogenases are enzymes mostly found in both anaerobic and aerobic 
prokaryotic organisms that can either produce molecular hydrogen (H2) or use it as an energy 
source (Vignais et al., 2001; Wu and Mandrand, 1993). Occasionally, hydrogenases can be 
found in some anaerobic eukaryotic organisms, enabling their survival in an oxygenless 
environment (Degli Esposti et al., 2016; Horner et al., 2000; Horner et al., 2002). They 





. Based on the metal clusters at their catalytic sites, hydrogenases are classified into three 
major types: [NiFe]-, [FeFe]-, and metal-free-hydrogenases; however, most of the described 
hydrogenases belong to the first two families (Vignais et al., 2001; Winkler et al., 2013; Wu 
and Mandrand, 1993). Because the majority of eukaryotic organisms are aerobes and do not 
need to use hydrogenases for anaerobic processes, hydrogenase-like proteins have lost their 
enzymatic abilities and have been found to fulfil other functions in eukaryotic cells. All types 
of hydrogenases typically contain iron-sulphur (Fe-S) clusters, inorganic cofactors that bind to 
protein ligands. Fe-S clusters have the ability to accept or donate single electrons, to execute 
oxidation and reduction reactions, and to support electron transport. In most cases, Fe-S 
clusters are coordinated by conserved cysteine residues (rarely by histidine residues) to ensure 
effective conduction between the catalytic metal sites and external donors and/or acceptors of 
electrons (Peters et al., 2015). Iron-sulphur proteins are present in all living organisms; they 
were first reported and described in bacteria (Beinert, 2000; Beinert et al., 1997; Beinert and 
Thomson, 1983). On the path of evolution, iron-sulphur proteins were transferred by 
endosymbiosis to eukaryotic mitochondria, cytoplasms, and nuclei (Ciofi-Baffoni et al., 2018; 
Lill, 2009). Most Fe-S proteins are composed of either a rhomboid cluster of two iron and two 
sulphide ions [2Fe-2S] or a cuboidal cluster of four iron and four sulphide ions [4Fe-4S]. To 
preclude a toxic effect of free iron and sulphide, the assembly of Fe-S clusters is precisely 
controlled in cells. It seems that many steps of these processes are universal to all organisms, 
although Fe-S proteins’ biosynthesis and maturation are much more complex in eukaryotes 
(Rouault, 2015). In eukaryotic cells, this process is split into mitochondrial iron-sulphur 




machinery. The ISC assembly machinery was inherited from endosymbiotic bacteria, and its 
components are homologues to the bacterial system (Ciofi-Baffoni et al., 2018; Lill, 2009). 
The processes of the mitochondrial ISC assembly system can be divided into three main 
functional steps: (1) de novo assembly of initial [2Fe-2S] cluster on ISCU2 scaffold protein 
(yeast Isu1), (2) transfer of [2Fe-2S] from ISCU2 to GLRX5 (Grx5), which functions as a 
[2Fe-2S] chaperon transferring the [2Fe-2S] to downstream acceptors, and (3) assembly of 
[4Fe-4S] cluster, followed by its insertion into mitochondrial protein. Within the first step, 
cysteine desulphurase complex NSF1-ISD11-ACP (Nsf1-Isd11-Acp1) removes sulphur from 
cysteine and transfers it to ISCU2 (Isu1). Next, the ISCU2 scaffold protein incorporates the 
iron from the mitochondrial pool to assemble the [2Fe-2S] cluster. In the next step, the de 
novo assembled [2Fe-2S] cluster is transferred from the ISCU2 scaffold protein to GLRX5 
(Grx5). GLRX5 protects the [2Fe-2S] cluster and transfers it to final [2Fe-2S] acceptors and 
to proteins involved in the final step of the mitochondrial ISC, that is, maturation of the [4Fe-
4S] target proteins. In the final step, ISCA1/ISCA2 (Isa1/Isa2) complex assembles the [4Fe-
4S] cluster, which in turn is distributed to target proteins (Ciofi-Baffoni et al., 2018; Lill, 
2009). ISC also has a fundamental function in the biosynthesis of cytosolic and nuclear Fe-S 
proteins. Disruption of the mitochondrial cysteine desulphurase complex Nfs1–Isd11 and the 
scaffold protein Isu1 in yeast has been found to be essential for extramitochondrial Fe/S 
protein biogenesis (Wiedemann et al., 2006). The components of ISC synthesise a sulphur-
containing intermediate, called (Fe-S)int, which is transported to the cytoplasm and serves as 
a source for the cytosolic and nuclear Fe/S clusters (Pandey et al., 2019). In line with the 
hypothesised impaired function of Atm1, the mitochondrial-cytosol transporter of this (Fe-
S)int component affects the biosynthesis of the cytosolic and nuclear Fe-S protein (Kispal et 
al., 1999). The (Fe-S)int component is further processed by the CIA machinery in the 
cytoplasm, fostering maturation of the cytosolic Fe-S protein and the transporter protein that 
supplies the Fe-S cluster to the cytosolic and nuclear target proteins. Exported (Fe-S)int is 
subsequently loaded on the NUBP1-NUBP2 scaffold protein complex (Cfd1-Nbp35). The 
scaffold protein complex uploads the Fe-S cluster into NARFL (Nar1), which together with 
CIAO1, CIA2B, MMS19, CIA2A, and CIAO1 (Cia1) forms the targeting complex (Ciofi-
Baffoni et al., 2018; Lill, 2009). Depending on the composition of the targeting complex, the 
Fe-S cluster is transferred to either the cytosolic or the nuclear effector Fe-S protein. In 
contrast to mitochondrial Fe-S proteins, cytosolic and nuclear Fe-S proteins function as 
enzymes (aconitase (important component of the citric acid cycle) or biotin and lipoate 




regulatory protein 1 (IRP1)) (Rouault, 2006); or control DNA repair mechanisms (ATP-
dependent DNA helicases XPD or FANCJ) (Rudolf et al., 2006). Recent studies on Fe-S 
protein pathways have revealed that both Nar1 and NARFL play an important role in the CIA, 
regulating the maturation of cytosolic and nuclear but not mitochondrial Fe-S proteins (Balk 
et al., 2004; Song and Lee, 2008). It has been shown that Nar1 is crucial to yeast cells’ 
function, as depletion of this protein causes growth arrest. Similarly, the knock-out of the 
Narfl gene is lethal in mice due to diminished activity of the cytosolic but not the 
mitochondrial Fe-S proteins (Song and Lee, 2011). In light of these results, I asked whether 
NARF can play a role in the maturation of the Fe-S proteins or is one of them. A comparative 
bioinformatics approach has also predicted that NARF is a Fe-S protein (Andreini et al., 
2016), but this has not been proven experimentally. During my study, I investigated this issue 
through generation of the NARF protein in bacteria; I was able to purify recombinant NARF, 
but I failed to detect Fe-S components (data not shown). It could be that the conditions 
applied for recombinant NARF expression were not optimal for the production of Fe-S 





isopropyl β- d-1-thiogalactopyranoside (IPTG) induction, I extracted the recombinant protein 





insufficient to induce expression of the Fe-S protein, and co-expression of the ISC 
components was essential for achieving high yields of active Fe-S holoprotein (Grawert et al., 
2004; Kriek et al., 2003; Nakamura et al., 1999). At the same time, aerobic conditions would 
perhaps have converted the exposed Fe-S clusters to unstable forms that would have quickly 
decomposed (Imlay, 2006). The described modification should be implemented in the 
protocol so that the experiment could be repeated. If NARF is a true Fe-S protein, it could be 
the additional player in CIA. In contrast to NARFL, the knock-down of the NARF protein in 
HeLa and Hep3B cells exerted no impact on the maturation of the cytosolic Fe-S protein 
(Song and Lee, 2008). Nevertheless, it could still regulate the maturation of the nuclear Fe-S 
protein. So far, there is no information on how the Fe-S cluster is transported from the 
cytoplasm, through the nuclear membrane, into the nucleus. Since NARF is observed on the 
nuclear membrane, it would seem to be a strong candidate. The KI mES cells generated 
within my study will form a suitable model to address this question. As illustrated in the 
results section, the NARF
p.H367R
 protein lost its nuclear localisation. If the NARF protein does 
in fact play a role in Fe-S transport, its mislocalisation should exert an impact on the function 
of the other Fe-S nuclear protein, e. g. DNA repair, maintenance of genomic stability, 





Figure 24: A model for biogenesis and maturation of cytosolic and nuclear Fe-S proteins in yeast. The Fe-S 
cluster intermediate is generated by mitochondrial iron-sulfur cluster (ISC) machinery and is exported from the 
mitochondrial matrix to the cytosol by Atm1. Cytosolic Fe-S protein assembly (CIA) machinery ensures 
transport and maturation of Fe-S proteins by assembly [Fe-S] cluster on scaffold protein complex Cfd1-Nbp35 
and transfer complex to subsequent cluster carrier – Nar1. Nar1 interacting with Cia1 provides scaffold and 
target transfer of [Fe-S] cluster to proper apoproteins resulting in generation of mature cytosolic and nuclear 
holoproteins; 1 = shortcut of the three major steps of [Fe-S] cluster synthesis provided by mitochondrial ISC 
assembly machinery (adopted and modified from Lill, 2009). 
 
6.8 Causative nature of p.His367Arg mutation in NARF 
The evidence gathered during my PhD research strongly indicates the causative nature of the 
identified p.His367Arg mutation in NARF. This is evinced in many points, including the de 
novo occurrence of the patient's heterozygous mutation at a residue that is highly conserved 
among various species of yeast, invertebrates, and mammals. In addition, a very important 
point here is that the mutation resides at exactly the same amino acid residue as the 
nematode's homologue OXY-4, which causes increased sensitivity to environmental oxygen 
alterations and increased mortality among nematode mutants. The most interesting issue 
discovered during my studies is that the point substitution identified in NARF leads to 
complete mislocalisation of the protein. Besides, NARF is able to form dimers, and 




mutation exerts a dominant negative effect on the wild-type protein, which may also explain 
the severe phenotype observed in a patient carrying the heterozygous form of the mutation. 
Furthermore, the mutation engenders dysfunction in cell proliferation abilities and impaired 
DNA damage repair mechanisms; these are both well-known hallmarks of ageing that also 
present in many progeroid syndromes. Finally, lamin A and CBX5, the interaction partners of 
NARF that were identified during the functional analyses conducted as part of this study, have 
also been associated with accelerated ageing disorders in humans and animal models. All the 
presented results provide genetic, functional, and morphological evidence for an important 
role of the identified mutation in the pathomechanisms of the progeroid syndrome afflicting 
our patient and indicate that the associated NARF variant may cause premature ageing 
diseases in humans. 
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